

ÖZGEÇMİŞ

Ad: Evren Doruk
Soyad: Engin
Doğum tarihi: 04/06/1974
Doğum yeri: Ankara, TÜRKİYE
Ev adresi: Mustafa Kemal Mah. 2137. Sok. 8/14 Eskişehir Yolu
06520 Çankaya, Ankara, TÜRKİYE
E telefonu: +90 312 2195868
İş adresi: Ankara Üniversitesi Biyoteknoloji Enstitüsü Merkez Laboratuvarı
(Rektörlük yanı) Tandoğan, Ankara
İş telefonu: +90 312 2225826 / 200
GSM: +90 532 2273923
e-mail: edoruk@gmail.com
ORCID ID: <https://orcid.org/0000-0001-9209-8858>
ResearcherID: <http://www.researcherid.com/rid/O-3604-2014>

Öğrenim

İlk ve orta öğrenim: TED Ankara Koleji 1980 – 1992
Tıp Fakültesi: Hacettepe Üniversitesi Tıp Fakültesi 1992 – 1997
Mikrobiyoloji ve Klinik Mikrobiyoloji Uzmanlığı: Hacettepe Üniversitesi Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dalı (*Helicobacter pylori*'de metronidazol direnci ve virülans faktörleri ile ilişkisi) 1998 – 2003
PhD: Gazi Üniversitesi Tıp Fakültesi 2003 - 2008
Tıbbi Mikrobiyoloji Anabilim Dalı (Antibiyotik etki mekanizmalarında “quorum sensing”in rolü)

İş Tecrübesi

1998 – 2003	Araştırma Görevlisi	Hacettepe Üniversitesi Tıp Fakültesi Mikrobiyoloji ve Klinik Mikrobiyoloji AD.
2004 – 2007	Öğretim Görevlisi	Gazi Üniversitesi Tıp Fakültesi Tıbbi Mikrobiyoloji AD.
2007 – 2009	Yardımcı Doçent	Gazi Üniversitesi Tıp Fakültesi Tıbbi Mikrobiyoloji AD.
2009 –	Yardımcı Doçent / Dr.Öğr.Üyesi	Ankara Üniversitesi Biyoteknoloji Enstitüsü

WOS SCI-core ve SCI-expanded veritabanlarında taranan hakemli dergilerde yayınlanmış makaleler

1. Poyraz BM, **Engin ED**, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. *Environ Toxicol Pharmacol.* 2021 Aug;86:103657.
2. Engin AB, **Engin ED**, Engin A. Current opinion in neurological manifestations of SARS-CoV-2 infection. *Curr Opin Toxicol.* 2021 Mar;25:49–56.
3. Engin AB, **Engin ED**, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. *Environ Toxicol Pharmacol.* 2021 Jan;81:103520.
4. Engin AB, **Engin ED**, Engin A. Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection. *Environ Toxicol Pharmacol.* 2020 Oct;79:103436.
5. Hanifehnezhad A, Kehribar ES, Oztop S, Sheraz A, Kasirga S, Ergunay K, Sevgen O, Yilmaz E, **Engin D**, Oguzoglu TC, Seker UOS, Ozkul A. Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR(-/-) mice. *Heliyon.* 2020 Sep;6(9):e05116.
6. Engin AB, **Engin ED**, Engin A. Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking. *Environ Toxicol Pharmacol.* 2020 Aug;78:103411.
7. Makey G, Galioglu S, Ghaffaril R, **Engin ED**, Yildirim G, Yavuz O, et al. Universality of dissipative self-assembly from quantum dots to human cells. *Nat Phys.* 2020 Jul;16(7):795-+.
8. Akışoğlu Ö, **Engin D**, Sarıçam S, Müştak HK, Şener B, Haşçelik G. [Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in patients with and without cystic fibrosis]. *Mikrobiyol Bul.* 2019 Jan;53(1):22–36.
9. Engin AB, **Engin ED**. Diverse Responses of Neurons and Monocytes to Titanium Dioxide Nanoparticle Exposure. *Turk J Immunol.* 2019;7(1):40–9.

10. **Engin ED**, Engin AB. Impact of glutamine on the effect of neopterin in methyl mercury-exposed neurons. *Pteridines*. 2018 Aug 1;29(1):104–13.
11. Engin AB, **Engin ED**, Karakus R, Aral A, Gulbahar O, Engin A. N-Methyl-D aspartate receptor-mediated effect on glucose transporter-3 levels of high glucose exposed-SH-SY5Y dopaminergic neurons. *Food Chem Toxicol*. 2017 Nov;109:465–71.
12. Engin AB, **Engin ED**, Golokhvast K, Spandidos DA, Tsatsakis AM. Glutamate-mediated effects of caffeine and interferon-gamma on mercury-induced toxicity. *Int J Mol Med*. 2017 May;39(5):1215–23.
13. Akoglu A, **Engin D**, Cakmakci ML. Some properties of C-phycoerythrin from a native strain *Anabaena affinis* isolated from Kovada Lake, Isparta, Turkey. *Indian J Geo-Mar Sci*. 2015 Apr;44(4):539–45.
14. Akcil G, Dogan I, Cengiz M, **Engin ED**, Dogan M, Unal S, et al. The role of interleukin-1 gene polymorphisms and *Helicobacter pylori* in gastroesophageal reflux disease. *Turk J Gastroenterol*. 2014 Dec;25:81–5.
15. Ozdemir B, Uraz A, Iscan D, Bozkurt S, Tuncer BB, **Engin D**, et al. Influence of Cervitec gel on periodontal health of patients wearing fixed orthodontic appliances. *J Dental Sci*. 2014 Sep;9(3):265–71.
16. Iriz E, Cirak MY, Zor MH, **Engin D**, Oktar L, Unal Y. Differential identification of atypical pneumonia pathogens in aorta and internal mammary artery related to ankle brachial index and walking distance. *J Surg Res*. 2013 Aug;183(2):537–41.
17. Karakan T, Kerem M, Cindoruk M, **Engin D**, Alper M, Akin O. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats. *Turk J Gastroenterol*. 2013 Apr;24(2):134–40.
18. Aykan SB, Caglar K, **Engin ED**, Sipahi AB, Sultan N, Cirak MY. Investigation of the Presence of Disinfectant Resistance Genes *qacA/B* in Nosocomial Methicillin-Resistant *Staphylococcus aureus* Isolates and Evaluation of Their In Vitro Disinfectant Susceptibilities. *Mikrobiyol Bul*. 2013 Jan;47(1):1–10.
19. Engin AB, **Engin ED**, Karahalil B. Effect of N-acetyl cysteine, Neopterin and Dexamethasone on the Viability of Titanium dioxide Nanoparticles Exposed Cell Lines. *Pteridines*. 2012 Dec;23(4):111–22.
20. Salihoglu U, Boynuegri D, **Engin D**, Duman AN, Gokalp P, Balos K. Bacterial Adhesion and Colonization Differences Between Zirconium Oxide and Titanium Alloys: An In Vivo Human Study. *Int J Oral Maxillofac Implants*. 2011 Feb;26(1):101–7.
21. Altinova AE, **Engin D**, Akbay E, Akturk M, Toruner F, Ersoy R, et al. Association of polymorphisms in the IL-18 and IL-12 genes with susceptibility to Type 1 diabetes in Turkish patients. *J Endocrinol Invest*. 2010 Aug;33(7):451–4.
22. Urgancioglu B, Bilgihan K, **Engin D**, Cirak MY, Hondur A, Hasanreisoglu B. Topical N-acetylcysteine reduces interleukin-1-alpha in tear fluid after laser subepithelial keratectomy. *Eur J Ophthalmol*. 2009 Aug;19(4):554–9.

23. Noral MY, Dogruman-Al F, **Engin ED**, Kustimur S, Babur C, Poyraz A. The Comparison of Polymerase Chain Reaction Directed to the 529 bp Gene and the B1 Gene in the Detection of Experimental Mouse Toxoplasmosis. *Turk Klin Tip Bilim Derg.* 2009 Feb;29(1):48–56.
24. Ozdemir E, Karabacak NI, Degertekin B, Cirak M, Dursun A, **Engin D**, et al. Could the simplified C-14 urea breath test be a new standard in noninvasive diagnosis of *Helicobacter pylori* infection? *Ann Nucl Med.* 2008 Aug;22(7):611–6.
25. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, **Engin D**, et al. Identification of *Helicobacter* species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. *Eur J Gastroenterol Hepatol.* 2008 Jan;20(1):33–6.
26. Iriz E, Cirak MY, **Engin ED**, Zor MH, Erer D, Ozdogan ME, et al. Detection of *Helicobacter pylori* DNA in aortic and left internal mammary artery biopsies. *Tex Heart Inst J.* 2008;35(2):130–5.
27. Kurukahvecioglu O, Koksa H, Gulbahar O, Erdem O, **Engin D**, Yazicioglu O, et al. Infliximab “TNF-alpha antagonist” decreases intraabdominal adhesions. *Saudi Med J.* 2007 Dec;28(12):1830–5.
28. Iriz E, Cirak MY, **Engin ED**, Zor MH, Erer D, Imren Y, et al. Effects of atypical pneumonia agents on progression of atherosclerosis and acute coronary syndrome. *Acta Cardiol.* 2007 Dec;62(6):593–8.
29. Uenaldi O, **Engin D**, Cirak MY. Comparison of agar screening plates and double disk synergy method in detection of extended-spectrum beta-lactamase production. *Mikrobiyol Bul.* 2007 Jul;41(3):369–76.
30. Aksoy DY, Aybar M, Ozaslan E, Kav T, **Engin D**, Ercis S, et al. Evaluation of the *Helicobacter pylori* stool antigen test (HpSA) for the detection of *Helicobacter pylori* infection and comparison with other methods. *Hepato-Gastroenterol.* 2003 Aug;50(52):1047–9.
31. Saltik IN, Demir H, **Engin D**, Ertunc OD, Akyon Y, Kocak N. The *cagA* status of *Helicobacter pylori* isolates from dyspeptic children in Turkey. *FEMS Immunol Med Microbiol.* 2003 May 25;36(3):147–9.
32. Anlar B, Ayhan A, Hotta H, Itoh M, **Engin D**, Barun S, et al. Measles virus RNA in tonsils of asymptomatic children. *J Paediatr Child Health.* 2002 Aug;38(4):424–5.
33. Anlar B, Pinar A, Anlar FY, **Engin D**, Ustacelebi S, Kocagoz T, et al. Viral studies in the cerebrospinal fluid in subacute sclerosing panencephalitis. *J Infect.* 2002 Apr;44(3):176–80.
34. Yalcin E, Ozcelik U, **Engin D**, Dogru D, Kiper N, Hascelik G. Does *Helicobacter pylori* cause bronchiectasis? *Acta Paediatr.* 2002;91(12):1403–1403.

Scopus veritabanında taranan hakemli dergilerde yayınlanmış makaleler

1. Us D, **Engin D**, Hasçelik G. Evaluation of Western blot method for the serological diagnosis of Helicobacter pylori infections. Mikrobiyoloji Bulteni. 2002;36(2):153–60.
2. **Engin D**. Hydrogen gas enhances the in vitro growth of Helicobacter pylori. Gazi Medical Journal. 2003;14(2):63–6.
3. Şahin E, Çöleri Cihan A, Aligholipour Farzani T, Földes K, **Engin ED**, Özkul A. Assessment of the immunogenicity and protective aspects of a dna vaccine targeting crimean congo hemorrhagic fever virus glycoprotein gc. Duzce Medical Journal. 2021;23(1):66–75.
4. **Engin ED**. The use of multiplexing technology in the immunodiagnosis of infectious agents. Journal of Immunoassay and Immunochemistry. 2019;40(1):109–22.

Diğer ulusal ve uluslararası hakemli dergilerde yayınlanmış makaleler

1. Engin A, **Engin D**. İntraabdominal sepsiste reaktif oksijen radikallerine konakçı ve bakterinin yanıtı. Ankara Cerrahi Dergisi. 2003;20:174–80.
2. Doğan Ö, Yalınay Çırak M, **Engin D**, Türet S. Klinik örneklerden izole edilen stafilokoklarda metisilin direnci ve çeşitli antibiyotiklere in-vitro duyarlılıkları. ANKEM Dergisi. 2005;19(1):39–42.
3. Atasoy Ulusoy Öİ, Görgül G, **Engin D**. Primer kök kanal enfeksiyonlarında Tannerella forsythia prevalansının 16S rRNA PCR ile incelenmesi. AÜ Diş Hek Fak Derg. 2010;37(1):7–11.
4. **Engin D**. Life Re-engineered with“Gene Compilers”–The Impact of Synthetic Biology on Biotechnology. Int J Biotechnol Bioeng. 2014;1:1–2.

Uluslararası kitap bölümü

1. Ozdemir N, Tuncel A, Duman M, Engin D, Denkbaz EB. Poly(n-isopropylacrylamide) (PNIPAM) Based Nanoparticles for In Vitro Plasmid DNA Delivery. In: Vaseashta A, Mihailescu IN, editors. Functionalized Nanoscale Materials, Devices and Systems [Internet]. Springer Netherlands; 2008 [cited 2014 Sep 11]. p. 325–30. Available from: http://link.springer.com/chapter/10.1007/978-1-4020-8903-9_25
2. Engin D. Chapter 4: Tryptophan Metabolites: A Microbial Perspective. In: Engin A, Engin AB, editors. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease [Internet]. Cham: Springer International Publishing; 2015 [cited 2015 Nov 3]. p.

- 75–94. (Molecular and Integrative Toxicology). Available from:
<http://link.springer.com/10.1007/978-3-319-15630-9>
3. Engin ED. Microbiota and Lipotoxicity. In: Obesity and Lipotoxicity. 1st ed. Springer; 2017. p. 247–60. (Advances in Experimental Medicine and Biology; vol. 960).
 4. Engin ED. Bacterial Protein Kinases. In: Engin AB, Engin A, editors. Protein Kinase-Mediated Decisions Between Life and Death [Internet]. Cham: Springer International Publishing Ag; 2021 [cited 2021 Nov 16]. p. 323–38. Available from:
<https://www.webofscience.com/wos/alldb/full-record/WOS:000624289200012>

Ulusal kitap bölümü

1. Ustaçelebi Ş, Engin D. HIV enfeksiyonu immünopatogenezi ve tanıda kullanılan yöntemler. Modern Tıp Seminerleri. 2000;10:11–26.

Uluslararası kongre bildirileri (SCI-Core dergilerde özeti basılmış)

2. Unal S, Cirak MY, Dumlu S, Karakan T, Engin D, Turet S, et al. Increased *Helicobacter pylori* clarithromycin resistance rates in patients with non-ulcer dyspepsia. *Gastroenterology*. 2006 Apr;130(4):A572–3.
3. Cirak MY, Engin D, Unal S, Dalgic B, Dumlu S, Turet S. Genotyping of *Helicobacter pylori* putative lipopolysaccharide synthesis protein locus as a candidate virulence marker. *Helicobacter*. 2007 Aug;12(4):387–387.
4. Cirak MY, Engin D, Unal S, Karakan T, Turet S, Dumlu S. Monitoring of *Helicobacter pylori* resistance to clarithromycin by real-time PCR assay in gastric biopsy specimens over a 4-year period in Turkey. *Helicobacter*. 2007 Aug;12(4):449–449.
5. Cirak MY, Ozdek A, Engin D, Karakan I, Unal S, Turet S. Does gastroesophageal acid reflux give rise to *Helicobacter pylori* in sinonasal mucosa? *Helicobacter*. 2007 Aug;12(4):467–467.
6. Unal S, Cirak M, Dumlu S, Karakan I, Engin D, Turet S, et al. Increased *Helicobacter pylori* clarithromycin resistance rates in patients with nonulcer dyspepsia. *Helicobacter*. 2007 Aug;12(4):390–390.
7. Unal S, Cirak MY, Dumlu S, Karakan I, Engin D, Turet S, et al. Increased *Helicobacter pylori* clarithromycin resistance rates in patients with nonulcer dyspepsia. *Helicobacter*. 2007 Aug;12(4):390–390.
8. Karakan T, Cindoruk M, Kerem M, Salman B, Engin D, Alper M, et al. Peroxisome proliferator-activated alpha agonist treatment increases trefoil factor family 3 expression and attenuates apoptosis in the liver tissue of bile duct ligated rats. *Journal of Hepatology*. 2008;48:S173–S173.

Uluslararası kongrelerde tam metni kogre kitapçığında basılmış sözlü bildiri ve posterler

1. Engin D, Kocagoz T. Real Time Colorimetric Physiological Monitoring of Microbial Cells. International Advanced Technologies Symposium Proceedings. Elazig, Turkey; 2011.
2. Engin D. Computer aided design in synthetic biology - The Gene Compiler [Internet]. Conference presented at: International ITU Molecular Biology and Genetics Student Congress'14; 2014; Suleyman Demirel Cultural Center ITU Ayazaga Campus, Istanbul, Turkey. Available from: <http://www.mbgkongre.itu.edu.tr/programme-speakers/>
3. Can C, Kolçak P, Yalınkılıç A, Engin D. Production of active human interferon alpha Escherichia coli cells. Poster presented at: 17th International Pharmaceutical Technology Symposium; 2014 Sep 8; Antalya / Turkey.
4. Engin D. The Gene Compiler – Computer Aided Design Tool for Synthetic Biology. Poster presented at: 17th International Pharmaceutical Technology Symposium; 2014 Sep 8; Antalya / Turkey.
5. Kolçak P, Can C, Engin D. Production of active human interferon gamma in Escherichia coli cells. Poster presented at: 17th International Pharmaceutical Technology Symposium; 2014 Sep 8; Antalya / Turkey.
6. Engin AB, Engin ED, Aral A, Gulbahar O, Engin A. Effect of KynA on N-methyl_D aspartate receptor-coupled glucose transporter-3 in SH-SY5H dopaminergic neurons exposed to high glucose in 36 th International Winter-Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics, Feb 2017 Innsbruck, Austria
7. Serim Ilday, Evren Engin, Ghaith Makey, Ozgun Yavuz, Denizhan Kesim, Onur Tokel, Oguz Gulseren, Fatih Ilday. Universal Dynamic Self-assembly: From Colloids to Microorganisms to Sub-10 nm Particles in APS March Meeting 2018, Los Angeles, California, US
8. Engin AB, Engin ED, Aral A, Gulbahar O, Engin A. The Effect of N-methyl-D- Aspartate Receptor Blockade by Kynurenic Acid on High Glucose and Insulin-Exposed SH-SY5Y Human Neuroblastoma Cells in Society of Toxicology 2017 Annual Meeting, Baltimore, US
9. D. Engin, O. Akisoglu, A. G. Hascelik. Optimization of Cultivation Conditions for Burkholderia Cenocepacia Biofilm Formation and Evaluation the Biofilm Production of Burkholderia Species Isolated from Cystic Fibrosis and Non-Cystic Fibrosis Patients in ASM Microbe 2018 June 7-11, Atlanta, US
10. Roujin Ghaffari(Presenter), Sezin Galigolu, Evren Doruk Engin, Serim Ilday. Abstract: H63.00011 : Dynamic self-organization of microorganisms far from equilibrium. APS March Meeting 2019 Volume 64, Number 2, Monday–Friday, March 4–8, 2019; Boston, Massachusetts. (Tuesday, March 5, 2019 4:54 PM–5:06 PM)

Ulusal kongrelerde sunulmuş sözlü bildiri ve posterler

1. Yalınkılıç A, Engin D. Escherichia coli'de siprofloksasin maruziyetinde sağ kalımda "quorum sensing" in rolü. In: Konuşma özetleri ve bildirileri kitabı. Belek, Antalya; 2014. p. 394. (Sözlü sunum)
2. Özkan Taylan A, Cansaran Duman D, Engin D. Usnik asit siklodekstrin inklüzyon komplekslerinin Leishmania major promastigotları üzerindeki etkisi. In: Konuşma özetleri ve bildirileri kitabı. Belek, Antalya; 2014. p. 340. (Poster)
3. Doruk Evren Engin. DiffProt: (Meta)proteom Karşılaştırma Aracı. 4. Ulusal Klinik Mikrobiyoloji Kongresi, 8 – 12 Kasım 2017, Antalya
4. Engin D, Ertüzün G, Soydemir E. Eriyik yağma modelleme ile üretilmiş malzemelerin ozon gazı ile sterilizasyonu. 4. Ulusal Klinik Mikrobiyoloji Kongresi, 8 – 12 Kasım 2017, Antalya


Uluslararası kongrelerde davetli konuşmalar

1. Engin D. Vaccine design and innate immune network. ISOPS-13: 13th International Symposium on Pharmaceutical Sciences June 22-25, Ankara, Turkey

Ulusal kongrelerde davetli konuşmalar

1. Doruk Engin. Antimikrobiyal direncin evrimi ve hastane enfeksiyonlarına etkisi. 3. Ulusal Klinik Mikrobiyoloji Kongresi – 2015, 18-22 Kasım 2015, Antalya
2. Doruk Engin. Canlı Fakat Kültürü Yapılamayan Bakteriler-Yeni Antimikrobiyal Keşfi İçin Buzdağının Su Altındaki Parçası mı? XXXVII. Türk Mikrobiyoloji Kongresi, 16 – 20 Kasım 2016, Antalya
3. Doruk Engin. Ne zaman, nerede, ne kadar biyoinformatik? 4. Ulusal Klinik Mikrobiyoloji Kongresi, 8 – 12 Kasım 2017, Antalya
4. Engin D. Mikrobiyotayı anlamak: Biyobelirteç olarak mikrobiyom. 5. Ulusal Klinik Mikrobiyoloji Kongresi, 28 Ekim – 1 Kasım 2019, İzmir, Türkiye

Uluslararası atıflar



1. Engin AB, Engin ED, Engin A. Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking. *Environ Toxicol Pharmacol.* 2020 Aug;78:103411.

1. Sahin I, Haymana C, Demir T, Demirci I, Tasci I, Atmaca A, et al. Clinical Characteristics and Outcomes of COVID-19 Patients with Overweight and Obesity: Turkish Nationwide Cohort Study (TurCObesity). *EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES.*

2. Maghsood F, Hassani D, Salimi V, Kardar GA, Khoshnoodi J, Ghaderi A, et al. Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. *VIRAL IMMUNOLOGY.*

3. Akter S, Zakia MA, Mofijur M, Ahmed SF, Vo D-VN, Khandaker G, et al. SARS-CoV-2 variants and environmental effects of lockdowns, masks and vaccination: a review. *ENVIRONMENTAL CHEMISTRY LETTERS.*

4. Binda F, Galazzi A, Marelli F, Gambazza S, Villa L, Vinci E, et al. Complications of prone positioning in patients with COVID-19: A cross-sectional study. *INTENSIVE AND CRITICAL CARE NURSING.* 2021 Dec;67.

5. Gupta S, Smith L, Diakiw A. Avoidance of COVID-19 for Children and Adolescents and Isolation Precautions. *PEDIATRIC CLINICS OF NORTH AMERICA.* 2021 Oct;68(5):1103–18.

6. do Couto AC, Kmetiuk LB, Delai RR, Drulla Brandao AP, Monteiro CO, Antoniassi da Silva LH, et al. High SARS-CoV-2 seroprevalence in persons

- experiencing homelessness and shelter workers from a day-shelter in Sao Paulo, Brazil. *PLOS NEGLECTED TROPICAL DISEASES*. 2021 Oct;15(10).
7. Moura AD, da Costa HHM, Correa VA, Lima AK de S, Lindoso JAL, De Gaspari E, et al. Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. *SCIENTIFIC REPORTS*. 2021 Sep 3;11(1).
 8. Poyraz BM, Engin ED, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. *ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY*. 2021 Aug;86.
 9. Lucidi D, Molinari G, Silvestri M, De Corso E, Guaraldi G, Mussini C, et al. Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. *INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY*. 2021 Aug;11(8):1249–52.
 10. Gujski M, Jankowski M, Rabczenko D, Gorynski P, Juszczuk G. Characteristics and Clinical Outcomes of 116,539 Patients Hospitalized with COVID-19-Poland, March-December 2020. *VIRUSES-BASEL*. 2021 Aug;13(8).
 11. Gomez-Zorita S, Milton-Laskibar I, Garcia-Arellano L, Gonzalez M, Portillo MP. An Overview of Adipose Tissue ACE2 Modulation by Diet and Obesity. Potential Implications in COVID-19 Infection and Severity. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2021 Aug;22(15).
 12. Papadopoulou SK, Mantzourou M, Koutridou D, Tassoulas E, Sakellaropoulou S, Biskanaki F, et al. COVID-19 disease, obesity and micronutrients: An updated narrative review of the literature. *NUTRITION & FOOD SCIENCE*. 2021 Jul 9;51(5):808–24.
 13. Leonel ACL da S, Ribeiro ILA, de Souza MLM, Kaminagakura E, Martelli-Junior H, Ferreti Bonan PR, et al. COVID-19, changes in smoking behaviour, and head and neck cancer: Current data and future perspectives. *ORAL ONCOLOGY*. 2021 Jul;118.
 14. Watanabe LM, Navarro AM, Seale LA. Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil. *NUTRIENTS*. 2021 Jun;13(6).
 15. Liao S-Y, Linderholm A, Showalter MR, Chen C-H, Fiehn O, Kenyon NJ. L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma. *OBSESITY SCIENCE & PRACTICE*. 2021 Jun;7(3):339–45.
 16. Hafner SJ. This is not a pipe - But how harmful is electronic cigarette smoke? *BIOMEDICAL JOURNAL*. 2021 Jun;44(3):227–34.
 17. Costagliola G, Spada E, Consolini R. Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19. *IMMUNITY INFLAMMATION AND DISEASE*. 2021 Jun;9(2):331–9.
 18. Cordon M, Eyestone E, Hutchison S, Dunlap D, Smith L, Williams RM, et al. A qualitative study exploring older smokers' attitudes and motivation toward quitting during the COVID-19 pandemic. *PREVENTIVE MEDICINE REPORTS*. 2021 Jun;22.
 19. Goncalves DA, Ribeiro V, Gualberto A, Peres F, Luconi M, Gameiro J. COVID-19 and Obesity: An Epidemiologic Analysis of the Brazilian Data. *INTERNATIONAL JOURNAL OF ENDOCRINOLOGY*. 2021 May 7;2021.
 20. Wendel S, Fontao-Wendel R, Fachini R, Candelaria G, Scuracchio P, Achkar R, et al. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of

CCP collections. TRANSFUSION. 2021 May;61(5):1447–60.

21. Gammone MA, D’Orazio N. Review: Obesity and COVID-19: A Detrimental Intersection. FRONTIERS IN ENDOCRINOLOGY. 2021 Apr 30;12.

22. Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and Infection, a Nuanced Relationship. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2021 Apr 23;2021.

23. Katoto PDMC, Brand AS, Bakan B, Obadia PM, Kuhangana C, Kayembe-Kitenge T, et al. Acute and chronic exposure to air pollution in relation with incidence, prevalence, severity and mortality of COVID-19: a rapid systematic review. ENVIRONMENTAL HEALTH. 2021 Apr 10;20(1).

24. Prinelli F, Bianchi F, Drago G, Ruggieri S, Sojic A, Jesuthasan N, et al. Association Between Smoking and SARS-CoV-2 Infection: Cross-sectional Study of the EPICOVID19 Internet-Based Survey. JMIR PUBLIC HEALTH AND SURVEILLANCE. 2021 Apr;7(4).

25. Demeulemeester F, de Punder K, van Heijningen M, van Doesburg F. Obesity as a Risk Factor for Severe COVID-19 and Complications: A Review. CELLS. 2021 Apr;10(4).

26. Abouzid M, El-Sherif DM, Elteuacy NK, Dahman NBH, Okasha SA, Ghozy S, et al. Influence of COVID-19 on lifestyle behaviors in the Middle East and North Africa Region: a survey of 5896 individuals. JOURNAL OF TRANSLATIONAL MEDICINE. 2021 Mar 30;19(1).

27. Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 2021 Mar 2;106.

28. Inchingolo AD, Inchingolo AM, Bordea IR, Malcangi G, Xhajanka E, Scarano A, et al. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. MICROORGANISMS. 2021 Mar;9(3).

29. Engin AB, Engin ED, Engin A. Current opinion in neurological manifestations of SARS-CoV-2 infection. CURRENT OPINION IN TOXICOLOGY. 2021 Mar;25:49–56.

30. Wang M, Wang C, Zhang L. Inflammatory endotypes of CRSwNP and responses to COVID-19. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY. 2021 Feb;21(1):8–15.

31. Hu P, Ma M, Jing Q, Ma Y, Gan L, Chen Y, et al. Retrospective study identifies infection related risk factors in close contacts during COVID-19 epidemic. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2021 Feb;103:395–401.

32. Wu Y, Zhan Q, Zhao Q. Long-term Air Pollution Exposure Impact on COVID-19 Morbidity in China. AEROSOL AND AIR QUALITY RESEARCH. 2021 Jan;21(1).

33. Rodriguez-Barranco M, Rivas-Garcia L, Quiles JL, Redondo-Sanchez D, Aranda-Ramirez P, Llopis-Gonzalez J, et al. The spread of SARS-CoV-2 in Spain: Hygiene habits, sociodemographic profile, mobility patterns and comorbidities. ENVIRONMENTAL RESEARCH. 2021 Jan;192.

34. Famiglietti A, Memoli JW, Khaitan PG. Are electronic cigarettes and vaping effective tools for smoking cessation? Limited evidence on surgical outcomes: a narrative review. JOURNAL OF THORACIC DISEASE. 2021 Jan;13(1):384–95.

35. Engin AB, Engin ED, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2021 Jan;81.

36. Melguizo Ibanez E, Zurita Ortega F, Ubago Jimenez JL, Gonzalez Valero G. Levels of adherence to the Mediterranean diet and emotional intelligence in students of the third cycle of elementary education from the province of Granada. *RETOS-NUEVAS TENDENCIAS EN EDUCACION FISICA DEPORTE Y RECREACION*. 2021;(40):264–71.
37. Ibanez EM, Ortega FZ, Jimenez JLU, Valero GG. Levels of adherence to the Mediterranean diet and emotional intelligence in students of the third cycle of elementary education from the province of Granada. *RETOS-NUEVAS TENDENCIAS EN EDUCACION FISICA DEPORTE Y RECREACION*. 2021;(40):264–71.
38. Altiook D, Savci EZ, Ozkara B, Alkan K, Namdar DS, Tuncer G, et al. Host variations in SARS-CoV-2 infection. *TURKISH JOURNAL OF BIOLOGY*. 2021;45(4):404–24.
39. Yanai H. Metabolic Syndrome and COVID-19. *CARDIOLOGY RESEARCH*. 2020 Dec;11(6):360–5.
40. Voinsky I, Gurwitz D. Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. *DRUG DEVELOPMENT RESEARCH*. 2020 Dec;81(8):1073–80.
41. Rogge MM, Gautam B. COVID-19: Epidemiology and clinical practice implications. *NURSE PRACTITIONER*. 2020 Dec;45(12):26–34.
42. Rogge MM, Gautam B. COVID-19 Epidemiology and clinical practice implications. *NURSE PRACTITIONER*. 2020 Dec;45(12):26–34.
43. Moreno Fernandez-Ayala DJ, Navas P, Lopez-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. *EXPERIMENTAL GERONTOLOGY*. 2020 Dec;142.
44. Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S. Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. *JOURNAL OF CLINICAL MEDICINE*. 2020 Dec;9(12).
45. Ferron P-J, Gicquel T, Megarbane B, Clement B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? *BIOCHIMIE*. 2020 Dec;179:266–74.
46. Ferrante G, Camussi E, Piccinelli C, Senore C, Armaroli P, Ortale A, et al. Did social isolation during the SARS-CoV-2 epidemic have an impact on the lifestyles of citizens? *EPIDEMIOLOGIA & PREVENZIONE*. 2020 Dec;44(5–6):353–62.
47. Dugail I, Amri E-Z, Vitale N. High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification. *BIOCHIMIE*. 2020 Dec;179:257–65.
48. Sparks MA, South AM, Badley AD, Baker-Smith CM, Batlle D, Bozkurt B, et al. Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System Pressing Needs and Best Research Practices. *HYPERTENSION*. 2020 Nov;76(5):1350–67.
49. Bordea IR, Xhajanka E, Candrea S, Bran S, Onisor F, Inchingolo AD, et al. Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. *MICROORGANISMS*. 2020 Nov;8(11).
50. Yanai H. Adiposity is the Crucial Enhancer of COVID-19. *CARDIOLOGY RESEARCH*. 2020 Oct;11(5):353–4.
51. Engin AB, Engin ED, Engin A. Dual function of sialic acid in gastrointestinal

- SARS-CoV-2 infection. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2020 Oct;79.
52. Banerjee M, Gupta S, Sharma P, Shekhawat J, Gauba K. Obesity and COVID-19: A Fatal Alliance. INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY. 2020 Oct;35(4):410–7.
53. Pun M, Turner R, Strapazzon G, Brugger H, Swenson ER. Lower Incidence of COVID-19 at High Altitude: Facts and Confounders. HIGH ALTITUDE MEDICINE & BIOLOGY. 2020 Sep 1;21(3):217–22.
54. Yan AF, Sun X, Zheng J, Mi B, Zuo H, Ruan G, et al. Perceived risk, behavior changes and Health-related outcomes during COVID-19 pandemic: Findings among adults with and without diabetes in China. DIABETES RESEARCH AND CLINICAL PRACTICE. 2020 Sep;167.
55. Adorni F, Prinelli F, Bianchi F, Giacomelli A, Pagani G, Bernacchia D, et al. Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOV19 Web-Based Survey. JMIR PUBLIC HEALTH AND SURVEILLANCE. 2020 Sep;6(3):461–74.
56. Yanai H. The Points of Action of Drugs for Treating COVID-19. JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2020 Aug;10(3–4):57–9.
57. Nasiri MJ, Haddadi S, Tahvildari A, Farsi Y, Arbabi M, Hasanzadeh S, et al. COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis. FRONTIERS IN MEDICINE. 2020 Jul 21;7.
58. Di Renzo L, Gualtieri P, Pivari F, Soldati L, Attina A, Cinelli G, et al. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. JOURNAL OF TRANSLATIONAL MEDICINE. 2020 Jun 8;18(1).
59. Matias JN, dos Santos Campanari GS, de Souza GA, Lima VM, Tofano RJ, Penteado Detregiachi CR, et al. Metabolic syndrome and COVID-19. AIMS BIOENGINEERING. 2020;7(4):242–53.
60. Hoshiyama T, Wada T, Nihonyanagi S, Kameda R, Yamaoka-Tojo M, Fukuda M, et al. Clinical and Microbiological Features of Asymptomatic SARS-CoV-2 Infection and Mild COVID-19 in Seven Crewmembers of a Cruise Ship. INTERNAL MEDICINE. 2020;59(24):3135–40.
2. Salihoglu U, Boynuegri D, Engin D, Duman AN, Gokalp P, Balos K. Bacterial Adhesion and Colonization Differences Between Zirconium Oxide and Titanium Alloys: An In Vivo Human Study. Int J Oral Maxillofac Implants. 2011 Feb;26(1):101–7.
1. Kniha K, Heussen N, Modabber A, Hoelzle F, Moehlhenrich SC. The effect of zirconia and titanium surfaces on biofilm formation and on host-derived immunological parameters. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021 Oct;50(10):1361–74.
 2. Inoue M, Nakano T, Shimomoto T, Kabata D, Shintani A, Yatani H. Multivariate analysis of the influence of prosthodontic factors on peri-implant bleeding index and marginal bone level in a molar site: A cross-sectional study. CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH. 2020 Dec;22(6):713–22.
 3. Herrmann H, Kern J-S, Kern T, Lautensack J, Conrads G, Wolfart S. Early and mature biofilm on four different dental implant materials: An in vivo human study. CLINICAL ORAL IMPLANTS RESEARCH. 2020 Nov;31(11):1094–104.
 4. Oeschger CE, Bosshardt DD, Roehling S, Gahlert M, Cochran DL, Janner SFM. Crestal bone response to loaded zirconia and titanium implants: a radiographic and histometric analysis in canines. CLINICAL ORAL INVESTIGATIONS. 2020 Oct;24(10):3609–17.

5. Linkevicius T, Valantiejiene V, Alkimavicius J, Gineviciute E, Andrijauskas R, Linkeviciene L. The Effect of a Polishing Protocol on the Surface Roughness of Zirconium Oxide. *INTERNATIONAL JOURNAL OF PROSTHODONTICS*. 2020 Apr;33(2):217–23.
6. Huang Y-S, Huang H-H. Effects of clinical dental implant abutment materials and their surface characteristics on initial bacterial adhesion. *RARE METALS*. 2019 Jun;38(6):512–9.
7. Degirmenci K, Kocak-Buyukdere A, Ekici B. Evaluation of reliability of zirconia materials to be used in implant-retained restoration on the atrophic bone of the posterior maxilla: A finite element study. *JOURNAL OF ADVANCED PROSTHODONTICS*. 2019 Apr;11(2):112–9.
8. Zembic A, Happe A. Implant Abutments. Happe A, Koerner G, editors. 2019. 225 p. (TECHNIQUES FOR SUCCESS WITH IMPLANTS IN THE ESTHETIC ZONE).
9. Stefany Meza-Siccha A, Angel Aguilar-Luis M, Silva-Caso W, Mazulis F, Barragan-Salazar C, del Valle-Mendoza J. In Vitro Evaluation of Bacterial Adhesion and Bacterial Viability of *Streptococcus mutans*, *Streptococcus sanguinis*, and *Porphyromonas gingivalis* on the Abutment Surface of Titanium and Zirconium Dental Implants. *INTERNATIONAL JOURNAL OF DENTISTRY*. 2019;2019.
10. Rodriguez AE, Monzavi M, Yokoyama CL, Nowzari H. Zirconia dental implants: A clinical and radiographic evaluation. *JOURNAL OF ESTHETIC AND RESTORATIVE DENTISTRY*. 2018 Dec;30(6):538–44.
11. Huh Y-H, Yang E-C, Park C-J, Cho L-R. In vitro evaluation of the polishing effect and optical properties of monolithic zirconia. *JOURNAL OF PROSTHETIC DENTISTRY*. 2018 Jun;119(6):994–9.
12. Sivaraman K, Chopra A, Narayan AI, Balakrishnan D. Is zirconia a viable alternative to titanium for oral implant? A critical review. *JOURNAL OF PROSTHODONTIC RESEARCH*. 2018 Apr;62(2):121–33.
13. Piras FF, Costa MD, de Mendonca LM, Rubo JH, Pegoraro LF. ESTHETIC REHABILITATION WITH ZIRCONIA ON TOOTH AND MORSE TAPER IMPLANT. *BIOSCIENCE JOURNAL*. 2018 Feb;34(1):260–7.
14. Kniha K, Milz S, Kniha H, Ayoub N, Hoelzle F, Modabber A. Peri-implant Crestal Bone Changes Around Zirconia Implants in Periodontally Healthy and Compromised Patients. *INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS*. 2018 Feb;33(1):217–22.
15. Kniha K, Schlegel KA, Kniha H, Hoelzle F, Modabber A, Kniha K. Peri-implant changes in papillary dimensions around zirconium dioxide implants in the esthetic area. *IMPLANTOLOGIE*. 2018;26(4):375–80.
16. Merli M, Bianchini E, Mariotti G, Moscatelli M, Piemontese M, Rappelli G, et al. Ceramic vs composite veneering of full arch implant-supported zirconium frameworks: assessing patient preference and satisfaction. A crossover double-blind randomised controlled trial. *EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY*. 2017 Sep 22;10(3):311–22.
17. Matos AO, Ricomini-Filho AP, Beline T, Ogawa ES, Costa-Oliveira BE, de Almeida AB, et al. Three-species biofilm model onto plasma-treated titanium implant surface. *COLLOIDS AND SURFACES B-BIOINTERFACES*. 2017 Apr 1;152:354–66.
18. Roehling S, Astasov-Frauenhoffer M, Hauser-Gerspach I, Braissant O, Woelfler H, Waltimo T, et al. In Vitro Biofilm Formation on Titanium and Zirconia Implant Surfaces. *JOURNAL OF PERIODONTOLOGY*. 2017 Mar;88(3):298–307.

19. Cionca N, Hashim D, Mombelli A. Zirconia dental implants: where are we now, and where are we heading? *PERIODONTOLOGY* 2000. 2017 Feb;73(1):241–58.
20. Hahnel S. Biofilms on dental implants. In: Deng Y, Lv W, editors. *BIOFILMS AND IMPLANTABLE MEDICAL DEVICES: INFECTION AND CONTROL*. 2017. p. 117–40.
21. Gahlert M, Kniha H, Weingart D, Schild S, Gellrich N-C, Bormann K-H. A prospective clinical study to evaluate the performance of zirconium dioxide dental implants in single-tooth gaps. *CLINICAL ORAL IMPLANTS RESEARCH*. 2016 Dec;27(12):E176–84.
22. Qian H, Zhang F, Jiao T. Mandibule rehabilitation after embolization of hemangioma with implant overdenture using existing endosseous implants: A clinical report. *JOURNAL OF PROSTHODONTIC RESEARCH*. 2016 Oct;60(4):332–6.
23. Huh Y-H, Park C-J, Cho L-R. Evaluation of various polishing systems and the phase transformation of monolithic zirconia. *JOURNAL OF PROSTHETIC DENTISTRY*. 2016 Sep;116(3):440–9.
24. Baixe S, Tenenbaum H, Etienne O. Microbial contamination of the implant-abutment connections: Review of the literature. *REVUE DE STOMATOLOGIE DE CHIRURGIE MAXILLO-FACIALE ET DE CHIRURGIE ORALE*. 2016 Feb;117(1):20–5.
25. Nam J, Tokutomi H. Using zirconia-based prosthesis in a complete-mouth reconstruction treatment for worn dentition with the altered vertical dimension of occlusion. *JOURNAL OF PROSTHETIC DENTISTRY*. 2015 Feb;113(2):81–5.
26. Haff A, Lof H, Gunne J, Sjogren G. A retrospective evaluation of zirconia-fixed partial dentures in general practices: An up to 13-year study. *DENTAL MATERIALS*. 2015 Feb;31(2):162–70.
27. Delgado-Ruiz RA, Luis Calvo-Guirado J, Abboud M, Piedad Ramirez-Fernandez M, Eduardo Mate-Sanchez J, Negri B, et al. Histologic and Histomorphometric Behavior of Microgrooved Zirconia Dental Implants with Immediate Loading. *CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH*. 2014 Dec;16(6):856–72.
28. Kopp S, Behrend D, Specht O, Trostmann D, Rosentritt M, Ottl P, et al. Materialographical Examination of three different Types of damaged Dental Implants. *PRAKTISCHE METALLOGRAPHIE-PRACTICAL METALLOGRAPHY*. 2014 Feb;51(2):127–45.
29. Yamane K, Ayukawa Y, Takeshita T, Furuhashi A, Yamashita Y, Koyano K. Bacterial adhesion affinities of various implant abutment materials. *CLINICAL ORAL IMPLANTS RESEARCH*. 2013 Dec;24(12):1310–5.
30. de Avila ED, de Molon RS, Palomari Spolidorio DM, Mollo F de A Jr. Implications of Surface and Bulk Properties of Abutment Implants and Their Degradation in the Health of Periodontal Tissue. *MATERIALS*. 2013 Dec;6(12):5951–66.
31. Miyazaki T, Nakamura T, Matsumura H, Ban S, Kobayashi T. Current status of zirconia restoration. *JOURNAL OF PROSTHODONTIC RESEARCH*. 2013 Oct;57(4):236–61.
32. do Nascimento C, Pita MS, Pedrazzi V, de Albuquerque Junior RF, Ribeiro RF. In vivo evaluation of *Candida* spp. adhesion on titanium or zirconia abutment surfaces. *ARCHIVES OF ORAL BIOLOGY*. 2013 Jul;58(7):853–61.
33. Zembic A, Boesch A, Jung RE, Haemmerle CHF, Sailer I. Five-year results of a randomized controlled clinical trial comparing zirconia and titanium abutments

- supporting single-implant crowns in canine and posterior regions. *CLINICAL ORAL IMPLANTS RESEARCH*. 2013 Apr;24(4):384–90.
34. Oshida Y, Oshida Y. Implant-Related Biological Reactions. 2013. 169 p. (BIOSCIENCE AND BIOENGINEERING OF TITANIUM MATERIALS, 2ND EDITION).
35. Yeo I-S, Kim H-Y, Lim KS, Han J-S. Implant surface factors and bacterial adhesion: a review of the literature. *INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS*. 2012 Oct;35(10):762–72.
36. van Brakel R, Meijer GJ, Verhoeven JW, Jansen J, de Putter C, Cune MS. Soft tissue response to zirconia and titanium implant abutments: an in vivo within-subject comparison. *JOURNAL OF CLINICAL PERIODONTOLOGY*. 2012 Oct;39(10):995–1001.
37. Kim H-Y, Yeo I-S, Lee J-B, Kim S-H, Kim D-J, Han J-S. Initial in vitro bacterial adhesion on dental restorative materials. *INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS*. 2012 Oct;35(10):773–9.
3. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, et al. Identification of *Helicobacter* species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. *Eur J Gastroenterol Hepatol*. 2008 Jan;20(1):33–6.
1. Kao T-W, Huang C-C. Recent Progress in Metabolic Syndrome Research and Therapeutics. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2021 Jul;22(13).
2. Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and Infection, a Nuanced Relationship. *CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*. 2021 Apr 23;2021.
3. Doulberis M, Papaefthymiou A, Srivastava DS, Exadaktylos AK, Katsinelos P, Kountouras J, et al. Update on the association between non-alcoholic fatty liver disease and *Helicobacter pylori* infection. *INTERNATIONAL JOURNAL OF CLINICAL PRACTICE*. 2021 Apr;75(4).
4. Buzas GM. *Helicobacter pylori* and non-alcoholic fatty liver disease. *MINERVA GASTROENTEROLOGICA E DIETOLOGICA*. 2020 Sep;66(3):267–79.
5. Abdel-Razik A, Mousa N, Elhelaly R, Elzehery R, Hasan AS, Abdelsalam M, et al. *Helicobacter pylori* as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study. *FRONTIERS IN MEDICINE*. 2020 Mar 24;7.
6. Sarsenbaeva AS, Ufimtsev KA, Domracheva EV. *Helicobacter pylori* infection and fatty liver. *Experimental and Clinical Gastroenterology Journal*. 2020;(6):146–53.
7. Polyzos SA, Kountouras J, Mantzoros CS. *Helicobacter pylori* infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction? *METABOLISM-CLINICAL AND EXPERIMENTAL*. 2019 Jul;96:III–V.
8. Polyzos SA, Kountouras J. *Helicobacter pylori* infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. *HELICOBACTER*. 2019 Jun;24(3).
9. Rizzatti G, Matteo MV, Ianiro G, Cammarota G, Franceschi F, Gasbarrini A. *Helicobacter pylori* in metabolic related diseases. *MINERVA GASTROENTEROLOGICA E DIETOLOGICA*. 2018 Sep;64(3):297–309.
10. Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, et al. *Helicobacter pylori* infection and liver diseases: Epidemiology and insights into

pathogenesis. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2018 Aug 28;24(32):3617–25.

11. German SV, Bobrovnitsky IP. Helicobacter pylori Infection and Hepatobiliary Pathology. *Russian Journal of Gastroenterology, Hepatology, Coloproctology*. 2018;28(4):15–22.

12. Cai O, Huang Z, Li M, Zhang C, Xi F, Tan S. Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease: A Single-Center Clinical Study. *GASTROENTEROLOGY RESEARCH AND PRACTICE*. 2018;2018.

13. Castano-Rodriguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. *BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY*. 2017 Dec;31(6):657–68.

14. Cheng D, He C, Ai H, Huang Y, Lu N. The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease. *FRONTIERS IN MICROBIOLOGY*. 2017 May 10;8.

15. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. *GUT MICROBES*. 2017;8(3):253–67.

16. Baeg MK, Yoon SK, Ko S-H, Noh Y-S, Lee I-S, Choi M-G. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2016 Feb 28;22(8):2592–600.

17. Li H, Ma L, Chen J, Zen W, Jin L, Xu X, et al. ZJU index is associated with prevalence of Helicobacter pylori infection in a Chinese population. *INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE*. 2016;9(11):22324–30.

18. Rabelo-Goncalves EMA, Roesler BM, Zeitune JMR. Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. *WORLD JOURNAL OF HEPATOLOGY*. 2015 Dec 28;7(30):2968–79.

19. Sumida Y, Kanemasa K, Imai S, Mori K, Tanaka S, Shimokobe H, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. *JOURNAL OF GASTROENTEROLOGY*. 2015 Sep;50(9):996–1004.

20. Polyzos SA, Nikolopoulos P, Stogianni A, Romiopoulos I, Katsinelos P, Kountouras J. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study. *Arq Gastroenterol*. 2014 Sep;51(3):261–8.

21. Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The Effect of Helicobacter pylori Eradication on Liver Fat Content in Subjects With Non-Alcoholic Fatty Liver Disease: A Randomized Open-Label Clinical Trial. *HEPATITIS MONTHLY*. 2013 Dec;13(12).

22. Li M, Shen Z, Li Y-M. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2013 Nov 7;19(41):7024–31.

23. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. *METABOLISM-CLINICAL AND EXPERIMENTAL*. 2013 Jan;62(1):121–6.

24. Garcia A, Feng Y, Parry NMA, McCabe A, Mobley MW, Lertpiriyapong K, et al. Helicobacter pylori infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis. *GUT MICROBES*. 2013;4(6):577–90.

25. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The Association Between

- Helicobacter pylori Infection and Insulin Resistance: A Systematic Review. *HELICOBACTER*. 2011 Apr;16(2):79–88.
26. Nakonieczna J, Stalke P, Abu Al-Soud W, Wadstrom T, Bielawski KP. Detection of Helicobacter rodentium-like DNA in the liver tissue of patients with chronic liver diseases by polymerase chain reaction-denaturing gradient gel electrophoresis and DNA sequence analysis. *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE*. 2010 Nov;68(3):201–7.
4. Iriz E, Cirak MY, Engin ED, Zor MH, Erer D, Ozdogan ME, et al. Detection of Helicobacter pylori DNA in aortic and left internal mammary artery biopsies. *Tex Heart Inst J*. 2008;35(2):130–5.
1. Dadashi M, Hajikhani B, Ghazi M, Yazdani S, Goudarzi M, Nasiri MJ, et al. The global prevalence of Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus and Herpes simplex virus in patients with coronary artery disease: A systematic review and meta-analysis. *MICROBIAL PATHOGENESIS*. 2021 Mar;152.
 2. Liu X-R, Xu Q, Xiao J, Deng Y-M, Tang Z-H, Tang Y-L, et al. Role of oral microbiota in atherosclerosis. *CLINICA CHIMICA ACTA*. 2020 Jul;506:191–5.
 3. Xia X, Zhang L, Chi J, Li H, Liu X, Hu T, et al. Helicobacter pylori Infection Impairs Endothelial Function Through an Exosome-Mediated Mechanism. *JOURNAL OF THE AMERICAN HEART ASSOCIATION*. 2020 Mar 17;9(6).
 4. Testerman TL, Semino-Mora C, Cann JA, Qiang B, Pena EA, Liu H, et al. Both diet and Helicobacter pylori infection contribute to atherosclerosis in pre- and postmenopausal cynomolgus monkeys. *PLOS ONE*. 2019 Sep 6;14(9).
 5. Chi J, Xia X, Zhang L, Liu X, Li H, Liu P, et al. Helicobacter Pylori Induces GATA3-Dependent Chitinase 3 Like 1 (CHI3L1) Upregulation and Contributes to Vascular Endothelial Injuries. *MEDICAL SCIENCE MONITOR*. 2019 Jun 30;25:4837–48.
 6. Biscetti F, Nardella E, Cecchini AL, Landolfi R, Flex A. The Role of the Microbiota in the Diabetic Peripheral Artery Disease. *MEDIATORS OF INFLAMMATION*. 2019;2019.
 7. Maev IV, Bakulin IG, Kurilovich SA, Bakulina NV, Andreev NG, Golubev NN. Helicobacter pylori and extragastrointestinal diseases: the proven facts and assumptions. *Russian Journal of Evidence-based Gastroenterology*. 2018;7(3):45–59.
 8. Yu X-J, Yang X, Feng L, Wang L-L, Dong Q-J. Association between Helicobacter pylori infection and angiographically demonstrated coronary artery disease: A meta-analysis. *EXPERIMENTAL AND THERAPEUTIC MEDICINE*. 2017 Feb;13(2):787–93.
 9. Ribaldone DG, Fagoonee S, Hickman I, Altruda F, Saracco GM, Pellicano R. Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? *MINERVA CARDIOANGIOLOGICA*. 2016 Dec;64(6):686–96.
 10. Ramezani-Binabaj M, Mobasher-Jannat A, Safiabadi M, Saburi A, Rezaee-Zavareh MS, Karimi-Sari H, et al. The Relationship between Helicobacter pylori Infection and Atherosclerosis: A Meta-analysis. *ERCIYES MEDICAL JOURNAL*. 2016 Sep;38(3):90–4.
 11. Budzynski J, Wisniewska J, Ciecierski M, Kedzia A. Association between Bacterial Infection and Peripheral Vascular Disease: A Review. *INTERNATIONAL JOURNAL OF ANGIOLOGY*. 2016 Mar;25(1):3–13.
 12. Haybar H, Assareh A, Sheikhi M, Molavi Z, Latifi SM, Beiranvand M, et al. Molecular Detection of Helicobacter pylori in the Atherosclerotic Coronary Plaques and Carotid Plaques: Is There Association with Development of Coronary Artery

- Disease? JOURNAL OF PURE AND APPLIED MICROBIOLOGY. 2015 Dec;9(4):2871–8.
13. Chmiela M, Gajewski A, Rudnicka K. Helicobacter pylori vs coronary heart disease - searching for connections. WORLD JOURNAL OF CARDIOLOGY. 2015 Apr 26;7(4):187–203.
 14. Chen S-N, Lian I, Chen Y-C, Ho J-D. INCREASED INCIDENCE OF PEPTIC ULCER DISEASE IN CENTRAL SEROUS CHORIORETINOPATHY PATIENTS A Population-Based Retrospective Cohort Study. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES. 2015 Feb;35(2):231–7.
 15. Sharma V, Aggarwal A. Helicobacter pylori: Does it add to risk of coronary artery disease. WORLD JOURNAL OF CARDIOLOGY. 2015 Jan 26;7(1):19–25.
 16. Budzynski J, Kozinski M, Klopocka M, Kubica JM, Kubica J. Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. CLINICAL RESEARCH IN CARDIOLOGY. 2014 Nov;103(11):855–86.
 17. Bogen KT. Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia. MEDICAL HYPOTHESES. 2013 Jan;80(1):83–93.
 18. Attaallah W, Yener N, Ugurlu MU, Manukyan M, Asmaz E, Aktan AO. Gallstones and Concomitant Gastric Helicobacter pylori Infection. GASTROENTEROLOGY RESEARCH AND PRACTICE. 2013;2013.
 19. Izadi M, Fazel M, Shanibandi SH, Saadat SH, Farahani MM, Nasserli MH, et al. Helicobacter species in the atherosclerotic plaques of patients with coronary artery disease. CARDIOVASCULAR PATHOLOGY. 2012 Aug;21(4):307–11.
 20. Park MJ, Choi SH, Kim D, Kang SJ, Chung SJ, Choi SY, et al. Association between Helicobacter pylori Seropositivity and the Coronary Artery Calcium Score in a Screening Population. GUT AND LIVER. 2011 Sep;5(3):321–7.
 21. Zeng L, Chen R, Ishigami K, Atsumi M, Koizumi Y, Sato K, et al. Association between human metapneumovirus seroprevalence and hypertension in elderly subjects in a long-term care facility. HYPERTENSION RESEARCH. 2011 Apr;34(4):474–8.
 22. Vladimirov B. Helicobacter pylori-associated Diseases. Boyanova L, editor. 2011. 161 p. (HELICOBACTER PYLORI).
 23. Pathak CM, Kaur B, Khanduja KL. C-14-Urea breath test is safe for pediatric patients. NUCLEAR MEDICINE COMMUNICATIONS. 2010 Sep;31(9):830–5.
 24. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and Extragastric Diseases. HELICOBACTER. 2009 Sep;14:58–68.
 25. Monteiro L, Oleastro M, Lehours P, Megraud F. Diagnosis of Helicobacter pylori Infection. HELICOBACTER. 2009 Sep;14:8–14.
5. Altinova AE, Engin D, Akbay E, Akturk M, Toruner F, Ersoy R, et al. Association of polymorphisms in the IL-18 and IL-12 genes with susceptibility to Type 1 diabetes in Turkish patients. J Endocrinol Invest. 2010 Aug;33(7):451–4.
1. Ali YBM, El-Gahel HE, Abdel-Hakem NE, Gadalla ME, El-Hefnawy MH, El-Shahat M. Association between IL-18 and IL-6 gene polymorphisms and the risk of T1D in Egyptian children. JOURNAL OF DIABETES AND METABOLIC DISORDERS. 2021 Jun;20(1):439–46.
 2. Campos LP, Graciolo V, Welter M, Lopes MS, Nesi-Franca S, Picheth G, et al. The IL18 rs1946518 and PTPN22 rs2476601 polymorphisms are not associated with adult- and childhood-onset type 1 diabetes mellitus. GENETICS AND MOLECULAR RESEARCH. 2020 Nov 30;19(4).

3. Keles S, Anik A, Cevik O, Abas BI, Anik A. Gingival crevicular fluid levels of interleukin-18 and tumor necrosis factor-alpha in type 1 diabetic children with gingivitis. *CLINICAL ORAL INVESTIGATIONS*. 2020 Oct;24(10):3623–31.
4. Xia Y, Liang Y, Guo S, Yu J-G, Tang M-S, Xu P-H, et al. Association between cytokine gene polymorphisms and ankylosing spondylitis susceptibility: a systematic review and meta-analysis. *POSTGRADUATE MEDICAL JOURNAL*. 2018 Sep;94(1115):508–16.
5. Esmailbeig M, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. *EUROPEAN CYTOKINE NETWORK*. 2017 Dec;28(4):127–40.
6. Xiao J-P, Wang X-R, Zhang S, Wang H-Y, Ye L, Pan H-F, et al. Association between rs6887695 and 3' -untranslated region polymorphisms within the interleukin-12B gene and susceptibility to autoimmune diseases in Asian and European population: A meta-analysis. *AUTOIMMUNITY*. 2016;49(4):277–84.
7. Linhartova PB, Kastovsky J, Lucanova S, Bartova J, Poskerova H, Vokurka J, et al. Interleukin-17A Gene Variability in Patients with Type 1 Diabetes Mellitus and Chronic Periodontitis: Its Correlation with IL-17 Levels and the Occurrence of Periodontopathic Bacteria. *MEDIATORS OF INFLAMMATION*. 2016;2016.
8. Li J, Zhang C, Wang J-B, Chen S-S, Zhang T-P, Li S, et al. Relationship between the IL12B (rs3212227) gene polymorphism and susceptibility to multiple autoimmune diseases: A meta-analysis. *MODERN RHEUMATOLOGY*. 2016;26(5):749–56.
9. Itzel Sanchez-Zamora Y, Juarez-Avelar I, Vazquez-Mendoza A, Hiriart M, Rodriguez-Sosa M. Altered Macrophage and Dendritic Cell Response in Mif -/- Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 Diabetes. *JOURNAL OF DIABETES RESEARCH*. 2016;2016.
10. Weaver JR, Nadler JL, Taylor-Fishwick DA. Interleukin-12 (IL-12)/STAT4 Axis Is an Important Element for beta-Cell Dysfunction Induced by Inflammatory Cytokines. *PLoS One*. 2015 Nov 10;10(11).
11. Lee YH, Kim J-H, Song GG. Interleukin-18 promoter-607 C/A and-137 G/C polymorphisms and susceptibility to type 1 diabetes: A meta-analysis. *HUMAN IMMUNOLOGY*. 2015 Aug;76(8):537–45.
12. Tang L, Wang L, Liao Q, Wang Q, Xu L, Bu S, et al. Genetic Associations with Diabetes: Meta-Analyses of 10 Candidate Polymorphisms. *PLOS ONE*. 2013 Jul 29;8(7).
13. Hadzija MP, Korolija M, Jemin N, Pavkovic I, Pavkovic P, Medvidovic EP, et al. Polymorphisms in the IL-18 and IL-12B genes and their association with the clinical outcome in Croatian patients with Type 1 diabetes. *GENE*. 2013 Jan 10;512(2):477–81.
14. Taylor-Fishwick DA, Weaver JR, Grzesik W, Chakrabarti S, Green-Mitchell S, Imai Y, et al. Production and function of IL-12 in islets and beta cells. *DIABETOLOGIA*. 2013 Jan;56(1):126–35.
15. Kim H-L, Cho SO, Kim S-Y, Kim S-H, Chung W-S, Chung S-H, et al. Association of interleukin-18 gene polymorphism with body mass index in women. *REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY*. 2012 Apr 24;10.
16. Troseid M, Arnesen H, Seljeflot I. Interleukin-18 in Metabolic Syndrome and Diabetes. Bagchi D, Sreejayan N, editors. 2012. 253 p. (*NUTRITIONAL AND THERAPEUTIC INTERVENTIONS FOR DIABETES AND METABOLIC SYNDROME*).
17. Matias MAT, Saunus JM, Ivanovski S, Walsh LJ, Farah CS. Accelerated wound healing phenotype in Interleukin 12/23 deficient mice. *JOURNAL OF*

INFLAMMATION-LONDON. 2011 Dec 20;8.

6. Anlar B, Pinar A, Anlar FY, Engin D, Ustacelebi S, Kocagoz T, et al. Viral studies in the cerebrospinal fluid in subacute sclerosing panencephalitis. *J Infect.* 2002 Apr;44(3):176–80.
 1. Miller KD, Matullo CM, Milora KA, Williams RM, O'Regan KJ, Rall GF. Immune-Mediated Control of a Dormant Neurotropic RNA Virus Infection. *JOURNAL OF VIROLOGY.* 2019 Sep;93(18).
 2. Jafri SK, Kumar R, Ibrahim SH. Subacute sclerosing panencephalitis - current perspectives. *PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS.* 2018;9:67–71.
 3. Spencer PS, Mazumder R, Palmer VS, Lasarev MR, Stadnik RC, King P, et al. Environmental, dietary and case-control study of Nodding Syndrome in Uganda: A post-measles brain disorder triggered by malnutrition? *JOURNAL OF THE NEUROLOGICAL SCIENCES.* 2016 Oct 15;369:191–203.
 4. Abuhandan M, Cece H, Calik M, Karakas E, Dogan F, Karakas O. An Evaluation of Subacute Sclerosing Panencephalitis Patients with Diffusion-Weighted Magnetic Resonance Imaging. *CLINICAL NEURORADIOLOGY.* 2013 Mar;23(1):25–30.
 5. Abuhandan M, Calik M, Almaz V, Taskin A, Cakmak A, Selek S. An evaluation of Neuropeptide Y status in subacute sclerosing panencephalitis patients. *CLINICA TERAPEUTICA.* 2013;164(3):E159–62.
 6. Souraud JB, Faivre A, Waku-Kouomou D, Gaillard T, Aouad N, Meaudre E, et al. Adult fulminant subacute sclerosing panencephalitis: pathological and molecular studies - a case report. *CLINICAL NEUROPATHOLOGY.* 2009 Jun;28(3):213–8.
 7. Titomanlio L, Soyah N, Evrard P, Husson I, Sterkers G, Guerin V, et al. Rituximab in subacute sclerosing panencephalitis, Titomanlio et al., 2007;11 : 43-5. *EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY.* 2007 Jul;11(4):247–8.
 8. Gungor S, Olmez A, Firat PA, Haliloglu G, Anlar B. Serum retinol and beta-carotene levels in subacute sclerosing panencephalitis. *JOURNAL OF CHILD NEUROLOGY.* 2007 Mar;22(3):341–3.
 9. Cavlek TV, Sternak SL, Zarkovic K, Della Marina BM, Sojat LC, Basnec A, et al. Subacute sclerosing panencephalitis - The continuing threat. *COLLEGIUM ANTHROPOLOGICUM.* 2006 Dec;30(4):959–63.
 10. Iwasaki T, Nonoda Y, Ishii M. Remission associated with human herpesvirus infection in West syndrome. *JOURNAL OF CHILD NEUROLOGY.* 2006 Oct;21(10):886–90.
 11. Gungor S, Anlar B, Turan N, Yilmaz H, Helps C, Harbour D. Antibodies to borna disease virus in subacute sclerosing panencephalitis. *PEDIATRIC INFECTIOUS DISEASE JOURNAL.* 2005 Sep;24(9):833–4.
 12. Anlar B. HHV-6 in CSF samples. *NEUROPEDIATRICS.* 2003 Dec;34(6):334–334.
7. Makey G, Galioglu S, Ghaffaril R, Engin ED, Yildirim G, Yavuz O, et al. Universality of dissipative self-assembly from quantum dots to human cells. *Nat Phys.* 2020 Jul;16(7):795–+.
 1. Chambonneau M, Grojo D, Tokel O, Ilday FO, Tzortzakis S, Nolte S. In-Volume Laser Direct Writing of Silicon-Challenges and Opportunities. *LASER & PHOTONICS REVIEWS.*
 2. Nizam US, Makey G, Barbier M, Kahraman SS, Demir E, Shafigh EE, et al. Dynamic evolution of hyperuniformity in a driven dissipative colloidal system. *JOURNAL OF PHYSICS-CONDENSED MATTER.* 2021 Jul 28;33(30).
 3. Xu D, Shi R, Sun Z-Y, Lu Z-Y. Mechanism of periodic field driven self-assembly process. *JOURNAL OF CHEMICAL PHYSICS.* 2021 Apr 14;154(14).

4. Oeztuerk FE, Lappe T, Hellmann G, Schmitt J, Klaers J, Vewinger F, et al. Observation of a non-Hermitian phase transition in an optical quantum gas. *SCIENCE*. 2021 Apr 2;372(6537):88-+.
 5. Ibanez J-J, Ramirez-Rosario B, Fernandez-Pozo LF, Brevik EC. Exploring the scaling law of geographical space: Gaussian versus Paretian thinking. *EUROPEAN JOURNAL OF SOIL SCIENCE*. 2021 Mar;72(2):495–509.
 6. Mays A, Ponsaing A, Schehr G. Tracy-Widom Distributions for the Gaussian Orthogonal and Symplectic Ensembles Revisited: A Skew-Orthogonal Polynomials Approach. *JOURNAL OF STATISTICAL PHYSICS*. 2021 Feb 1;182(2).
 7. Skinner DJ, Song B, Jeckel H, Jelli E, Drescher K, Dunkel J. Topological Metric Detects Hidden Order in Disordered Media. *PHYSICAL REVIEW LETTERS*. 2021 Jan 27;126(4).
 8. Valente D, Brito F, Werlang T. Quantum dissipative adaptation. *COMMUNICATIONS PHYSICS*. 2021 Jan 19;4(1).
 9. Hu X, Li F, Xia F, Wang Q, Lin P, Wei M, et al. Dynamic nanoassembly-based drug delivery system (DNDDS): Learning from nature. *ADVANCED DRUG DELIVERY REVIEWS*. 2021;175.
 10. Wright A, Gerstner E, Brierley R, Trabesinger A, Chiao M, Georgescu I, et al. 15 years of Nature Physics. *NATURE PHYSICS*. 2020 Oct;16(10):999–1005.
 11. Levin M, Sorkin R, Pine D, Granek R, Bernheim-Groswasser A, Roichman Y. Kinetics of actin networks formation measured by time resolved particle-tracking microrheology. *SOFT MATTER*. 2020 Sep 7;16(33):7869–76.
 12. Forman CJ. Controlling control-A primer in open-source experimental control systems. *PLOS BIOLOGY*. 2020 Sep;18(9).
 13. Bisker G. Dissipate your way to self-assembly. *NATURE PHYSICS*. 2020 Jul;16(7):707–8.
8. Iriz E, Cirak MY, Engin ED, Zor MH, Erer D, Imren Y, et al. Effects of atypical pneumonia agents on progression of atherosclerosis and acute coronary syndrome. *Acta Cardiol*. 2007 Dec;62(6):593–8.
1. Khademi F, Vaez H, Momtazi-Borojeni AA, Majnooni A, Banach M, Sahebkar A. Bacterial infections are associated with cardiovascular disease in Iran: a meta-analysis. *ARCHIVES OF MEDICAL SCIENCE*. 2019;15(4):902–11.
 2. Wang S-H, Chien W-C, Chung C-H, Lin F-H, Peng C-K, Chian C-F, et al. Tuberculosis increases the risk of peripheral arterial disease: A nationwide population-based study. *RESPIROLOGY*. 2017 Nov;22(8):1670–6.
 3. Chung W-S, Hsu W-H, Lin C-L, Kao C-H. Mycoplasma pneumonia increases the risk of acute coronary syndrome: a nationwide population-based cohort study. *QJM-AN INTERNATIONAL JOURNAL OF MEDICINE*. 2015 Sep 1;108(9):697–703.
 4. Chung W-S, Lin C-L, Hung C-T, Chu Y-H, Sung F-C, Kao C-H, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. *INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE*. 2014 Jan;18(1):79–83.
 5. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. *INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES*. 2013 Dec;17(12):E1125–9.
 6. Iriz E, Cirak MY, Zor MH, Engin D, Oktar L, Unal Y. Differential identification of atypical pneumonia pathogens in aorta and internal mammary artery related to ankle brachial index and walking distance. *JOURNAL OF SURGICAL RESEARCH*. 2013 Aug;183(2):537–41.

7. Liou T-H, Wu C-W, Hao W-R, Hsu M-I, Liu J-C, Lin H-W. Risk of myocardial infarction in women with pelvic inflammatory disease. *INTERNATIONAL JOURNAL OF CARDIOLOGY*. 2013 Jul 31;167(2):416–20.
 8. Hao W-R, Lin H-W, Chao P-Z, Wu C-W, Yen T-H, Liu J-C, et al. Risk of myocardial infarction in patients with rhinosinusitis. *ATHEROSCLEROSIS*. 2013 Jan;226(1):263–8.
 9. Petyaev IM, Zigangirova NA, Petyaev AM, Pashko UP, Didenko LV, Morgunova EU, et al. ISOLATION OF CHLAMYDIA PNEUMONIAE FROM SERUM SAMPLES OF THE PATIENTS WITH ACUTE CORONARY SYNDROME. *INTERNATIONAL JOURNAL OF MEDICAL SCIENCES*. 2010;7(4):181–90.
 10. Di Pietro M, Schiavoni G, Del Piano M, Shaik Y, Boscolo P, Caraffa A, et al. CHLAMYDIA PNEUMONIAE AND ATHEROSCLEROSIS: THE ROLE OF MAST CELLS. *JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS*. 2009 Jun;23(2):65–9.
 11. Dabiri H, Rezadehbashi M, Badami N, Aghanouri R, Ahmadi H, Khoramizadeh MR, et al. Detection of Chlamydia pneumoniae in Atherosclerotic Plaques of Patients in Tehran, Iran. *JAPANESE JOURNAL OF INFECTIOUS DISEASES*. 2009 May;62(3):195–7.
9. Kurukahvecioglu O, Koksa H, Gulbahar O, Erdem O, Engin D, Yazicioglu O, et al. Infliximab “TNF-alpha antagonist” decreases intraabdominal adhesions. *Saudi Med J*. 2007 Dec;28(12):1830–5.
1. Junga A, Pilmane M, Abola Z, Volrats O. Tumor necrosis factor alpha, protein gene product 9.5, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 presence in congenital intra-abdominal adhesions in children under one year of age. *ARCHIVES OF MEDICAL SCIENCE*. 2021;17(1):92–9.
 2. Hyoju SK, Morrison S, Gul S, Gharedaghi MH, Mussa M, Najibi M, et al. Intestinal alkaline phosphatase decreases intraperitoneal adhesion formation. *JOURNAL OF SURGICAL RESEARCH*. 2017 Feb;208:84–92.
 3. Bayhan Z, Zeren S, Kocak FE, Kocak C, Akcilar R, Kargi E, et al. Antiadhesive and anti-inflammatory effects of pirfenidone in postoperative intra-abdominal adhesion in an experimental rat model. *JOURNAL OF SURGICAL RESEARCH*. 2016 Apr;201(2):348–55.
 4. Hashemzaei AM, Badrooze BA, Tabrizian CK, Iranshahi DM, Shahraki EMK, Khatibani FEA, et al. EFFECTS OF LUTEOLIN ON INTRA PERITONEAL ADHESION BANDS IN RAT. *JOURNAL OF FUNDAMENTAL AND APPLIED SCIENCES*. 2016;8:1–11.
 5. Yildiz T, Ilce Z, Yildirim M, Akdogan M, Yurumez Y, Varlikli O, et al. Antienflamatuar and antiadhesive effect of clioquinol. *INTERNATIONAL JOURNAL OF SURGERY*. 2015 Mar;15:17–22.
 6. Mohammadpour AH, Tavassoli A, Khakzad MR, Zibae E, Afshar M, Hashemzaei M, et al. Effect of gold nanoparticles on postoperative peritoneal adhesions in rats. *NANOMEDICINE JOURNAL*. 2015 SUM;2(3):211–6.
 7. Uysal B, Demirbag S, Poyrazoglu Y, Cayci T, Yesildaglar N, Guven A, et al. Medical ozone therapy decreases postoperative uterine adhesion formation in rats. *ARCHIVES OF GYNECOLOGY AND OBSTETRICS*. 2012 Nov;286(5):1201–7.
 8. Cashman JD, Kennah E, Shuto A, Winternitz C, Springate CMK. Fucoidan Film Safely Inhibits Surgical Adhesions in a Rat Model. *JOURNAL OF SURGICAL RESEARCH*. 2011 Dec;171(2):495–503.
 9. Petrovich YuA, Yarema IV, Kichenko SM, Urtaev BM. Study of Drug Transport

- between the Blood and Lymph in the Predominant Direction. *BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE*. 2009 Mar;147(3):357–60.
10. Cahill RA, Redmond HP. Cytokine orchestration in post-operative peritoneal adhesion formation. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2008 Aug 21;14(31):4861–6.
10. Aksoy DY, Aybar M, Ozaslan E, Kav T, Engin D, Ercis S, et al. Evaluation of the Helicobacter pylori stool antigen test (HpSA) for the detection of Helicobacter pylori infection and comparison with other methods. *Hepato-Gastroenterol*. 2003 Aug;50(52):1047–9.
1. Best LMJ, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. *COCHRANE DATABASE OF SYSTEMATIC REVIEWS*. 2018;(3).
 2. Blanco S, Forne M, Lacoma A, Prat C, Angel Cuesta M, Fuenzalida L, et al. Evaluation of a latex agglutination test (PYLOGEN) for the detection of Helicobacter pylori in stool specimens. *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE*. 2009 Apr;63(4):349–53.
 3. Blanco S, Forne M, Lacoma A, Prat C, Cuesta MA, Latorre I, et al. Comparison of stool antigen immunoassay methods for detecting Helicobacter pylori infection before and after eradication treatment. *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE*. 2008 Jun;61(2):150–5.
 4. Whitters AD, Carson HJ, Eilers SG, Bernstein NP. Immunoperoxidase in the interpretation of discordant histologic and urease findings for Helicobacter pylori. *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*. 2007 Jun;15(2):199–202.
 5. Dominguez J, Forne M, Blanco S, Prat C, Gali N, Latorre I, et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection before and after eradication therapy. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*. 2006 Jun 15;23(12):1735–40.
 6. Alborzi A, Soltani J, Pourabbas B, Oboodi B, Haghighat M, Hayati M, et al. Prevalence of Helicobacter pylori infection in children (south of Iran). *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE*. 2006 Apr;54(4):259–61.
 7. Li Y-H, Guo H, Zhang P-B, Zhao X-Y, Da S-P. Clinical value of Helicobacter pylori stool antigen test, ImmunoCard STAT HpSA, for detecting H pylori infection. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2004 Mar 15;10(6):913–4.
 8. Buhling F, Koch G, Wex T, Heimburg A, Vieth M, Leodolter A, et al. Simultaneous detection and differentiation of anti-Helicobacter pylori antibodies by flow microparticle immunofluorescence assay. *CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY*. 2004 Jan;11(1):131–6.
11. Engin AB, Engin ED, Engin A. Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection. *Environ Toxicol Pharmacol*. 2020 Oct;79:103436.
1. Dhar C, Sasmal A, Diaz S, Verhagen A, Yu H, Li W, et al. Are sialic acids involved in COVID-19 pathogenesis? *GLYCOBIOLOGY*. 2021 Sep;31(9):1068–71.
 2. Poyraz BM, Engin ED, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. *ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY*. 2021 Aug;86.
 3. Kenney SP, Wang Q, Vlasova A, Jung K, Saif L. Naturally Occurring Animal Coronaviruses as Models for Studying Highly Pathogenic Human Coronaviral Disease. *VETERINARY PATHOLOGY*. 2021 May;58(3):438–52.

4. Ryzhikov AB, Onkhonova GS, Imatdinov IR, Gavrilova EV, Maksyutov RA, Gordeeva EA, et al. Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro. *BIOCHEMISTRY-MOSCOW*. 2021 Mar;86(3):243–7.
5. Engin AB, Engin ED, Engin A. Current opinion in neurological manifestations of SARS-CoV-2 infection. *CURRENT OPINION IN TOXICOLOGY*. 2021 Mar;25:49–56.
6. Allen JD, Watanabe Y, Chawla H, Newby ML, Crispin M. Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition. *JOURNAL OF MOLECULAR BIOLOGY*. 2021 Feb 19;433(4).
7. Fantini J, Chahinian H, Yahsi N. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*. 2021 Jan 29;538:132–6.
8. Engin AB, Engin ED, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. *ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY*. 2021 Jan;81.
9. Ryzhikov AB, Onkhonova GS, Imatdinov IR, Gavrilova EV, Maksyutov RA, Gordeeva EA, et al. RECOMBINANT S PROTEIN OF SARS-CoV-2 in vitro IS CAPABLE OF BINDING GLYCANS OF THE LACTOSAMINE FAMILY. *Biokhimiya*. 2021;86(3):291–6.
10. Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. *ACS INFECTIOUS DISEASES*. 2020 Nov 13;6(11):2844–65.
12. Engin AB, Engin ED, Golokhvast K, Spandidos DA, Tsatsakis AM. Glutamate-mediated effects of caffeine and interferon-gamma on mercury-induced toxicity. *Int J Mol Med*. 2017 May;39(5):1215–23.
 1. Han B, Garcia-Mendoza D, van den Berg H, van den Brink NW. Modulatory Effects of Mercury (II) Chloride (HgCl₂) on Chicken Macrophage and B-Lymphocyte Cell Lines with Viral-Like Challenges In Vitro. *ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY*. 2021 Oct;40(10):2813–24.
 2. Guzel M, Naziroglu M, Akpınar O, Cınar R. Interferon Gamma-Mediated Oxidative Stress Induces Apoptosis, Neuroinflammation, Zinc Ion Influx, and TRPM2 Channel Activation in Neuronal Cell Line: Modulator Role of Curcumin. *INFLAMMATION*. 2021 Oct;44(5):1878–94.
 3. Lv N, Ma K, Li R, Liang P, Liang P, Gao X. Sublethal and lethal effects of the imidacloprid on the metabolic characteristics based on high-throughput non-targeted metabolomics in *Aphis gossypii* Glover. *ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY*. 2021 Apr 1;212.
 4. Karaulov AV, Renieri EA, Smolyagin AI, Mikhaylova IV, Stadnikov AA, Begun DN, et al. Long-term effects of chromium on morphological and immunological parameters of Wistar rats. *FOOD AND CHEMICAL TOXICOLOGY*. 2019 Nov;133.
 5. Lee HJ, Spandidos DA, Tsatsakis A, Margina D, Izotov BN, Yang SH. Neuroprotective effects of *Scrophularia buergeriana* extract against glutamate-induced toxicity in SH-SY5Y cells. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE*. 2019 May;43(5):2144–52.
 6. Algarve TD, Assmann CE, Cadona FC, Machado AK, Manica-Cattani MF, Sato-Miyata Y, et al. Guarana improves behavior and inflammatory alterations triggered by methylmercury exposure: an in vivo fruit fly and in vitro neural cells study. *ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH*. 2019 May;26(15):15069–83.
 7. Castellano P, Prevedel L, Valdebenito S, Eugenin EA. HIV infection and latency

- induce a unique metabolic signature in human macrophages. *SCIENTIFIC REPORTS*. 2019 Mar 8;9.
8. Jakaria Md, Park S-Y, Haque MdE, Karthivashan G, Kim I-S, Ganesan P, et al. Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors. *FRONTIERS IN MOLECULAR NEUROSCIENCE*. 2018 Aug 29;11.
9. Engin ED, Engin AB. Impact of glutamine on the effect of neopterin in methyl mercury-exposed neurons. *PTERIDINES*. 2018 Feb;29(1):104–13.
10. Engin AB, Engin ED, Karakus R, Aral A, Gulbahar O, Engin A. N-Methyl-D aspartate receptor-mediated effect on glucose transporter-3 levels of high glucose exposed-SH-SY5Y dopaminergic neurons. *FOOD AND CHEMICAL TOXICOLOGY*. 2017 Nov;109:465–71.
13. Saltik IN, Demir H, Engin D, Ertunc OD, Akyon Y, Kocak N. The *cagA* status of *Helicobacter pylori* isolates from dyspeptic children in Turkey. *FEMS Immunol Med Microbiol*. 2003 May 25;36(3):147–9.
1. Sterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2019 Sep 7;25(33):4870–84.
 2. Bahadori A, Hossein Somi M, Doran F, Eftekharsadat A, Kizilyildirim S, Esmaeillou M, et al. Comparative analysis of selected *cagPAI* genes and different *vacA* genotypes in Iranian and Turkish *H. pylori*-positive patients suffering from gastric adenocarcinoma and active chronic gastritis. *TURKISH JOURNAL OF MEDICAL SCIENCES*. 2017;47(3):916–22.
 3. Selimoglu MA, Karabiber H, Otlu B, Yildirim O, Ozer A, Samdanci E. Correlation of clinical, endoscopic, and histological findings with virulence factors in children with *Helicobacter pylori* gastritis. *EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY*. 2014 Jun;26(6):602–6.
 4. Erdogdu C, Saribas Z, Yilmaz YA. Detection of *cagA* and *vacA* genotypes of *Helicobacter pylori* isolates from a university hospital in Ankara region, Turkey. *TURKISH JOURNAL OF MEDICAL SCIENCES*. 2014;44(1):126–32.
 5. Ozbey G, Dogan Y, Demiroren K. Prevalence of *Helicobacter pylori* virulence genotypes among children in Eastern Turkey. *WORLD JOURNAL OF GASTROENTEROLOGY*. 2013 Oct 21;19(39):6585–9.
 6. Saribas Z, Demir H, Temizel INS, Simsek H, Ozen H, Akyon Y. DETECTION OF *cagA* PREVALENCE IN CLINICAL ISOLATES OF *HELICOBACTER PYLORI*. *MIKROBIYOLOJI BULTENI*. 2010 Jul;44(3):461–5.
 7. Homan M, Luzar B, Kocjan BJ, Orel R, Mocilnik T, Shrestha M, et al. Prevalence and Clinical Relevance of *cagA*, *vacA*, and *iceA* Genotypes of *Helicobacter pylori* Isolated From Slovenian Children. *JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION*. 2009 Sep;49(3):289–96.
 8. Janulaityte-Gunther D, Kucinskiene R, Kupcinskis L, Pavilonis A, Labanauskas L, Cizauskas A, et al. The humoral immune response to *Helicobacter pylori* infection in children with gastrointestinal symptoms. *FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY*. 2005 May 1;44(2):205–12.
 9. Aydin F, Kaklikkaya N, Ozgur O, Cubukcu K, Kilic A, Tosun I, et al. Distribution of *vacA* alleles and *cagA* status of *Helicobacter pylori* in peptic ulcer disease and non-ulcer dyspepsia. *CLINICAL MICROBIOLOGY AND INFECTION*. 2004 Dec;10(12):1102–4.
14. Ozdemir E, Karabacak NI, Degertekin B, Cirak M, Dursun A, Engin D, et al. Could the simplified C-14 urea breath test be a new standard in noninvasive diagnosis of *Helicobacter pylori*

infection? *Ann Nucl Med.* 2008 Aug;22(7):611–6.

1. Best LMJ, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, et al. Non-invasive diagnostic tests for *Helicobacter pylori* infection. *COCHRANE DATABASE OF SYSTEMATIC REVIEWS.* 2018;(3).
 2. Zhou Q, Li L, Ai Y, Pan Z, Guo M, Han J. Diagnostic accuracy of the C-14-urea breath test in *Helicobacter pylori* infections: a meta-analysis. *WIENER KLINISCHE WOCHENSCHRIFT.* 2017 Jan;129(1–2):38–45.
 3. Ferwana M, Abdulmajeed I, Alhaji Ahmed A, Madani W, Firwana B, Hasan R, et al. Accuracy of urea breath test in *Helicobacter pylori* infection: Meta-analysis. *WORLD JOURNAL OF GASTROENTEROLOGY.* 2015 Jan 28;21(4):1305–14.
 4. Rifaioglu EN, Aydogan F, Bulbul Sen B, Sen T, Ekiz O. Investigation into the frequency of *Helicobacter pylori* infection with carbon 14 urea breath test in patients with vitiligo. *TURKISH JOURNAL OF MEDICAL SCIENCES.* 2014 Dec;44(6):1051–4.
 5. Mansour-Ghanaei F, Sanaei O, Joukar F. Clinical Validation of an Office-Based C-14-UBT (Heliprobe) for *H. pylori* Diagnosis in Iranian Dyspeptic Patients. *GASTROENTEROLOGY RESEARCH AND PRACTICE.* 2011;2011.
 6. Boyanova L. Microbiology and Characteristics of *Helicobacter pylori*. Boyanova L, editor. 2011. 29 p. (*HELICOBACTER PYLORI*).
 7. Nagiyev T, Koksall F, Abayli B, Yula E. A Comparison of Culture and GLMM-PCR Methods for Detecting *Helicobacter Pylori* in Antral and Corpus Biopsy Specimens in Patients with Gastrointestinal Disorders. *TURKIYE KLINIKLERI TIP BILIMLERI DERGISI.* 2010 Jun;30(3):919–24.
15. Engin AB, Engin ED, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. *Environ Toxicol Pharmacol.* 2021 Jan;81:103520.
1. Krupa A, Kowalska I. The Kynurenine Pathway-New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.* 2021 Sep;22(18).
 2. Liu Z, Wang C, Wang X, Van Schepdael A. On-line screening of indoleamine 2,3-dioxygenase 1 inhibitors by partial filling capillary electrophoresis combined with rapid polarity switching. *JOURNAL OF CHROMATOGRAPHY A.* 2021 Aug 16;1651.
 3. Poyraz BM, Engin ED, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. *ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY.* 2021 Aug;86.
 4. Jafarzadeh A, Nemati M, Jafarzadeh S. Contribution of STAT3 to the pathogenesis of COVID-19. *MICROBIAL PATHOGENESIS.* 2021 May;154.
 5. Weisberg SP, Ural BB, Farber DL. Tissue-specific immunity for a changing world. *CELL.* 2021 Mar 18;184(6):1517–29.
 6. Pojero F, Candore G, Caruso C, Di Bona D, Groneberg DA, Ligotti ME, et al. The Role of Immunogenetics in COVID-19. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.* 2021 Mar;22(5).
 7. Bontempi E. The Europe second wave of COVID-19 infection and the Italy "strange " situation. *ENVIRONMENTAL RESEARCH.* 2021 Feb;193.
16. Engin AB, Engin ED, Karakus R, Aral A, Gulbahar O, Engin A. N-Methyl-D aspartate receptor-mediated effect on glucose transporter-3 levels of high glucose exposed-SH-SY5Y dopaminergic neurons. *Food Chem Toxicol.* 2017 Nov;109:465–71.
1. Engin AB, Engin A. Risk of Alzheimer's disease and environmental bisphenol A

- exposure. *CURRENT OPINION IN TOXICOLOGY*. 2021 Mar;25:36–41.
2. Engin AB, Engin A. Alzheimer's Disease and Protein Kinases. In: Engin A, Engin A, editors. *PROTEIN KINASE-MEDIATED DECISIONS BETWEEN LIFE AND DEATH*. 2021. p. 285–321.
 3. Arabadzhi SS, Zharkov MN, Kuchurov IV, Zlotin SG. Synthesis of Chiral N-Nitro-oxazolidin-2-ones and O-(beta-Nitraminoalkyl) Carbamates in Liquefied 1,1,1,2-Tetrafluoroethane Medium. *SYNTHESIS-STUTTGART*. 2020 Nov 17;52(22):3485–91.
 4. Lira J, Valencia D, Barazorda H, Cardenas-Garcia J, Gomez B. Effect of substituents on 3(S)-amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one: a DFT study. *THEORETICAL CHEMISTRY ACCOUNTS*. 2019 Jan;138(1).
 5. Engin AB, Engin A. Nanoparticles and neurotoxicity: Dual response of glutamatergic receptors. In: Sharma A, Sharma H, editors. *NANONEUROPROTECTION AND NANONEUROTOXICOLOGY*. 2019. p. 281–303.
 6. Taleb O, Patte-Mensah C, Meyer L, Kemmel V, Geoffroy P, Miesch M, et al. Evidence for effective structure-based neuromodulatory effects of new analogues of neurosteroid allopregnanolone. *JOURNAL OF NEUROENDOCRINOLOGY*. 2018 Feb;30(2).
 7. Engin ED, Engin AB. Impact of glutamine on the effect of neopterin in methyl mercury-exposed neurons. *PTERIDINES*. 2018 Feb;29(1):104–13.
17. Karakan T, Kerem M, Cindoruk M, Engin D, Alper M, Akin O. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats. *Turk J Gastroenterol*. 2013 Apr;24(2):134–40.
1. Nia AM, Khanipov K, Barnette BL, Ullrich RL, Golovko G, Emmett MR. Comparative RNA-Seq transcriptome analyses reveal dynamic time-dependent effects of Fe-56, O-16, and Si-28 irradiation on the induction of murine hepatocellular carcinoma. *BMC GENOMICS*. 2020 Jul 1;21(1).
 2. Wu X, Zheng H, Yang R, Luan X, Zhang L, Jin Q, et al. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-alpha-mediated fatty acid oxidation. *AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM*. 2019 Sep;317(3):E436–45.
 3. Lustgarten MS, Fielding RA. Metabolites Associated With Circulating Interleukin-6 in Older Adults. *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES*. 2017 Sep;72(9):1277–83.
 4. Zhang L, Ren F, Zhang X, Wang X, Shi H, Zhou L, et al. Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. *DISEASE MODELS & MECHANISMS*. 2016 Jul 1;9(7):799–809.
 5. El-Sheikh AAK, Rifaai RA. Peroxisome Proliferator Activator Receptor (PPAR)-gamma Ligand, but Not PPAR-alpha, Ameliorates Cyclophosphamide- Induced Oxidative Stress and Inflammation in Rat Liver. *PPAR RESEARCH*. 2014;2014.
18. Aykan SB, Caglar K, Engin ED, Sipahi AB, Sultan N, Cirak MY. Investigation of the Presence of Disinfectant Resistance Genes qacA/B in Nosocomial Methicillin-Resistant *Staphylococcus aureus* Isolates and Evaluation of Their In Vitro Disinfectant Susceptibilities. *Mikrobiyol Bul*. 2013 Jan;47(1):1–10.
1. Ignak S, Nakipoglu Y, Gurler B. Frequency of antiseptic resistance genes in clinical staphylococci and enterococci isolates in Turkey. *ANTIMICROBIAL RESISTANCE*

- AND INFECTION CONTROL. 2017 Aug 30;6.
2. Kampf G. Acquired resistance to chlorhexidine - is it time to establish an "antiseptic stewardship" initiative? JOURNAL OF HOSPITAL INFECTION. 2016 Nov;94(3):213–27.
 3. Guo L, Long M, Huang Y, Wu G, Deng W, Yang X, et al. Antimicrobial and disinfectant resistance of Escherichia coli isolated from giant pandas. JOURNAL OF APPLIED MICROBIOLOGY. 2015 Jul;119(1):55–64.
19. Hanifehnezhad A, Kehribar ES, Oztop S, Sheraz A, Kasirga S, Ergunay K, et al. Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR(-/-) mice. Heliyon. 2020 Sep;6(9):e05116.
1. Sahin E, Bozdayi G, Yigit S, Muftah H, Dizbay M, Tunccan OG, et al. Genomic characterization of SARS-CoV-2 isolates from patients in Turkey reveals the presence of novel mutations in spike and nsp12 proteins. JOURNAL OF MEDICAL VIROLOGY. 2021 Oct;93(10):6016–26.
 2. Ergunay K, Kaya M, Serdar M, Akyon Y, Yilmaz E. A cross-sectional overview of SARS-CoV-2 genome variations in Turkey. TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI. 2021 Oct;46(5):491–8.
 3. Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. LANCET. 2021 Jul 17;398(10296):213–22.
 4. Younes S, Younes N, Shurrab F, Nasrallah GK. Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review. REVIEWS IN MEDICAL VIROLOGY. 2021 Jul;31(4).
 5. Guo Q, Zhao Y, Li J, Liu J, Yang X, Guo X, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. CELL HOST & MICROBE. 2021 Feb 10;29(2):222–+.
20. Anlar B, Ayhan A, Hotta H, Itoh M, Engin D, Barun S, et al. Measles virus RNA in tonsils of asymptomatic children. J Paediatr Child Health. 2002 Aug;38(4):424–5.
1. Gromov D, Bulla I, Romero-Severson EO. Systematic evaluation of the population-level effects of alternative treatment strategies on the basic reproduction number. JOURNAL OF THEORETICAL BIOLOGY. 2019 Feb 7;462:381–90.
 2. Terry J, Brown K, Hiebert J, Al-Rawahi GN, Moxham JP, Krajden M, et al. Measles Lymphadenopathy in a Child With PFAPA Syndrome. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY. 2018 Oct;21(5):497–501.
 3. Yeshuroon-Koffler K, Shemer-Avni Y, Keren-Naus A, Goldbart AD. Detection of Common Respiratory Viruses in Tonsillar Tissue of Children with Obstructive Sleep Apnea. PEDIATRIC PULMONOLOGY. 2015 Feb;50(2):187–95.
 4. Proenca-Modena JL, Pereira Valera FC, Jacob MG, Buzatto GP, Saturno TH, Lopes L, et al. High Rates of Detection of Respiratory Viruses in Tonsillar Tissues from Children with Chronic Adenotonsillar Disease. PLOS ONE. 2012 Aug 3;7(8).
 5. Suvilehto J, Roivainen M, Seppanen M, Meri S, Hovi T, Carpen O, et al. Rhinovirus/enterovirus RNA in tonsillar tissue of children with tonsillar disease. JOURNAL OF CLINICAL VIROLOGY. 2006 Mar;35(3):292–7.
21. Akcil G, Dogan I, Cengiz M, Engin ED, Dogan M, Unal S, et al. The role of interleukin-1 gene polymorphisms and Helicobacter pylori in gastroesophageal reflux disease. Turk J Gastroenterol. 2014 Dec;25:81–5.
1. Picos A, Vulturar R, Picos A, Chis A, Chiorean I, Piciu A, et al. Interleukin-1A and interleukin-1B gene polymorphisms in gastroesophageal reflux disease.

- EXPERIMENTAL AND THERAPEUTIC MEDICINE. 2020 Oct;20(4):3394–8.
2. Shakhathreh MAK, Khabour OF, Alzoubi KH, BaniHani MN, Abu Siniyeh A, Bashir NA, et al. The Influence of IL-1B Gene Polymorphisms on H. pylori Infection and Triple Treatment Response Among Jordanian Population. APPLICATION OF CLINICAL GENETICS. 2020;13:139–45.
 3. Ren H-Y, Wen L-S, Geng Y-H, Huang J-B, Liu J-F, Shen D-Y, et al. Association between IL-1B gene polymorphisms and Helicobacter pylori infection: A meta-analysis. MICROBIAL PATHOGENESIS. 2019 Dec;137.
 4. Miftahussurur M, Doohan D, Nusi IA, Adi P, Rezkitha YAA, Waskito LA, et al. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLOS ONE. 2018 Nov 14;13(11).
22. Cirak MY, Engin D, Unal S, Karakan T, Turet S, Dumlu S. Monitoring of Helicobacter pylori resistance to clarithromycin by real-time PCR assay in gastric biopsy specimens over a 4-year period in Turkey. Helicobacter. 2007 Aug;12(4):449–449.
1. Kocazeybek B, Tokman HB. Prevalence of Primary Antimicrobial Resistance of H-pylori in Turkey: A Systematic Review. HELICOBACTER. 2016 Aug;21(4):251–60.
 2. Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence Factors and Antibiotic Resistance in Children With Helicobacter pylori Gastritis. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2014 May;58(5):608–12.
 3. Ozden A, Seven G, Bektas M. Effectiveness of different treatment regimens in helicobacter pylori eradication: Ten-year experience of a single institution. TURKISH JOURNAL OF GASTROENTEROLOGY. 2010 Sep;21(3):218–23.
 4. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The Modified Sequential Treatment Regimen Containing Levofloxacin for Helicobacter pylori Eradication in Turkey. HELICOBACTER. 2009 Dec;14(6):520–4.
23. Yalcin E, Ozcelik U, Engin D, Dogru D, Kiper N, Hascelik G. Does Helicobacter pylori cause bronchiectasis? Acta Paediatr. 2002;91(12):1403–1403.
1. Dhar C, Sasmal A, Diaz S, Verhagen A, Yu H, Li W, et al. Are sialic acids involved in COVID-19 pathogenesis? GLYCOBIOLOGY. 2021 Sep;31(9):1068–71.
 2. Poyraz BM, Engin ED, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2021 Aug;86.
 3. Kenney SP, Wang Q, Vlasova A, Jung K, Saif L. Naturally Occurring Animal Coronaviruses as Models for Studying Highly Pathogenic Human Coronaviral Disease. VETERINARY PATHOLOGY. 2021 May;58(3):438–52.
 4. Ryzhikov AB, Onkhonova GS, Imatdinov IR, GavriloVA EV, Maksyutov RA, Gordeeva EA, et al. Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro. BIOCHEMISTRY-MOSCOW. 2021 Mar;86(3):243–7.
 5. Engin AB, Engin ED, Engin A. Current opinion in neurological manifestations of SARS-CoV-2 infection. CURRENT OPINION IN TOXICOLOGY. 2021 Mar;25:49–56.
 6. Allen JD, Watanabe Y, Chawla H, Newby ML, Crispin M. Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition. JOURNAL OF MOLECULAR BIOLOGY. 2021 Feb 19;433(4).
 7. Fantini J, Chahinian H, Yahi N. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2021 Jan 29;538:132–6.

8. Engin AB, Engin ED, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2021 Jan;81.
9. Ryzhikov AB, Onkhonova GS, Imatdinov IR, Gavrilova EV, Maksyutov RA, Gordeeva EA, et al. RECOMBINANT S PROTEIN OF SARS-CoV-2 in vitro IS CAPABLE OF BINDING GLYCANS OF THE LACTOSAMINE FAMILY. Biokhimiya. 2021;86(3):291–6.
10. Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. ACS INFECTIOUS DISEASES. 2020 Nov 13;6(11):2844–65.
24. Akısoğlu Ö, Engin D, Sarıçam S, Müştak HK, Şener B, Hasçelik G. [Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in patients with and without cystic fibrosis]. Mikrobiyol Bul. 2019 Jan;53(1):22–36.
 1. Onem E, Sarisu HC, Ozaydin AG, Muhammed MT, Ak A. Phytochemical profile, antimicrobial, and anti-quorum sensing properties of fruit stalks of Prunus avium L. LETTERS IN APPLIED MICROBIOLOGY. 2021 Oct;73(4):426–37.
 2. Shao X, Xie Y, Zhang Y, Liu J, Ding Y, Wu M, et al. Novel therapeutic strategies for treating Pseudomonas aeruginosa infection. EXPERT OPINION ON DRUG DISCOVERY. 2020 Dec 1;15(12):1403–23.
25. Akoglu A, Engin D, Cakmakci ML. Some properties of C-phycocyanin from a native strain Anabaena affinis isolated from Kovada Lake, Isparta, Turkey. Indian J Geo-Mar Sci. 2015 Apr;44(4):539–45.
 1. Kaur S, Khattar JIS, Singh Y, Singh DP, Ahluwalia AS. Extraction, purification and characterisation of Phycocyanin from Anabaena fertilissima PUPCCC 410.5: as a natural and food grade stable pigment. JOURNAL OF APPLIED PHYCOLOGY. 2019 Jun;31(3):1685–96.
 2. Jawaharraj K, Shivani K, Shakambari G, Kumar RS, Ashokkumar B, Varalakshmi P. Agro-Industrial Waste Based Phycocyanin Production from Oscillatoria sp 50A: daf-16 Modulating Effect in Caenorhabditis elegans and p53 Dependent Apoptosis in HeLa cells. CHEMISTRYSELECT. 2017 Dec 21;2(36):11989–94.
26. Engin ED. Tryptophan Metabolites: A Microbial Perspective. In: Engin A, Engin AB, editors. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease [Internet]. Godalming: Springer-Verlag London Ltd; 2015 [cited 2021 Nov 16]. p. 75–94. Available from: <https://www.webofscience.com/wos/alldb/full-record/WOS:000375189200005>
 1. Wang Z, Xiao Q, Zhuang J, Feng T, Ho C-T, Song S. Characterization of Aroma-Active Compounds in Four Yeast Extracts Using Instrumental and Sensory Techniques. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. 2020 Jan 8;68(1):267–78.
 2. Antonia Alvarez-Fernandez M, Fernandez-Cruz E, Carmen Garcia-Parrilla M, Troncoso AM, Mattivi F, Vrhovsek U, et al. Saccharomyces cerevisiae and Torulaspora delbrueckii Intra- and Extra-Cellular Aromatic Amino Acids Metabolism. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. 2019 Jul 17;67(28):7942–53.
27. Ozdemir B, Uraz A, Iscan D, Bozkurt S, Tuncer BB, Engin D, et al. Influence of Cervitec gel on periodontal health of patients wearing fixed orthodontic appliances. J Dental Sci. 2014 Sep;9(3):265–71.
 1. Yan Y, Zheng B, Lekbach Y, Liu X, Zheng Y, Xu D, et al. D-leucine enhances antibiofilm activity of chlorhexidine against caries-causing Streptococcus mutans biofilm. INTERNATIONAL BIODETERIORATION & BIODEGRADATION. 2021 Feb;157.

2. Fatima F, Mahmood HT, Fida M, Sukhia RH. Effectiveness of antimicrobial gels on gingivitis during fixed orthodontic treatment: A systematic review and meta-analysis. *INTERNATIONAL ORTHODONTICS*. 2020 Mar;18(1):10–21.
28. Engin AB, Engin ED, Karahalil B. Effect of N-acetyl cysteine, Neopterin and Dexamethasone on the Viability of Titanium dioxide Nanoparticles Exposed Cell Lines. *Pteridines*. 2012 Dec;23(4):111–22.
 1. Engin AB, Engin ED. Diverse Responses of Neurons and Monocytes to Titanium Dioxide Nanoparticle Exposure. *TURKISH JOURNAL OF IMMUNOLOGY*. 2019;7(1):40–9.
 2. Piperigkou Z, Karamanou K, Engin AB, Gialeli C, Docea AO, Vynios DH, et al. Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics. *FOOD AND CHEMICAL TOXICOLOGY*. 2016 May;91:42–57.
29. Urgancioglu B, Bilgihan K, Engin D, Cirak MY, Hondur A, Hasanreisoglu B. Topical N-acetylcysteine reduces interleukin-1-alpha in tear fluid after laser subepithelial keratectomy. *Eur J Ophthalmol*. 2009 Aug;19(4):554–9.
 1. Gonzalez-Garcia MJ, Murillo GM, Pinto-Fraga J, Garcia N, Fernandez I, Maldonado MJ, et al. Clinical and tear cytokine profiles after advanced surface ablation refractive surgery: A six-month follow-up. *EXPERIMENTAL EYE RESEARCH*. 2020 Apr;193.
30. Noral MY, Dogruman-Al F, Engin ED, Kustimur S, Babur C, Poyraz A. The Comparison of Polymerase Chain Reaction Directed to the 529 bp Gene and the B1 Gene in the Detection of Experimental Mouse Toxoplasmosis. *Turk Klin Tip Bilim Derg*. 2009 Feb;29(1):48–56.
 1. Kornacka A, Cybulska A, Moskwa B. Comparison of sensitivity of two primer sets for the detection of *Toxoplasma gondii* DNA in wildlife. *ACTA PARASITOLOGICA*. 2018 Sep;63(3):634–9.
 2. Hunt PW. Molecular diagnosis of infections and resistance in veterinary and human parasites. *VETERINARY PARASITOLOGY*. 2011 Aug 4;180(1–2):12–46.
31. Poyraz BM, Engin ED, Engin AB, Engin A. The effect of environmental diesel exhaust pollution on SARS-CoV-2 infection: The mechanism of pulmonary ground glass opacity. *Environ Toxicol Pharmacol*. 2021 Aug;86:103657.
 1. Ishmatov A. “SARS-CoV-2 is transmitted by particulate air pollution”: Misinterpretations of statistical data, skewed citation practices, and misuse of specific terminology spreading the misconception. *ENVIRONMENTAL RESEARCH*. 2022 Mar;204.
32. Engin AB, Engin ED, Engin A. Current opinion in neurological manifestations of SARS-CoV-2 infection. *Curr Opin Toxicol*. 2021 Mar;25:49–56.
 1. Becker RC. Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series. *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*. 2021 Oct;52(3):692–707.
33. Ozdemir N, Tuncel A, Duman M, Engin D, Denkbaz EB. Poly(n-Isopropylacrylamide) (pnipam) Based Nanoparticles for in Vitro Plasmid Dna Delivery. In: Vaseashta A, Milhailescu IN, editors. *Functionalized Nanoscale Materials, Devices and Systems* [Internet]. Dordrecht: Springer; 2008 [cited 2021 Nov 16]. p. 325-+. Available from: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIConfProc&SrcApp=UA&KeyAID=10.1007%2F978-1-4020-8903-9_25&DestApp=DOI&SrcAppSID=C6Q5ASjl4lwuYj279rK&SrcJTitle=FUNCTIONALIZED+NANOSCALE+MATERIALS

%2C+DEVICES+AND+SYSTEMS&DestDOIRegistrantName=Springer-Verlag

1. Adibfar A, Amoabediny G, Eslaminejad MB, Mohamadi J, Bagheri F, Doulabi BZ. VEGF delivery by smart polymeric PNIPAM nanoparticles affects both osteogenic and angiogenic capacities of human bone marrow stem cells. MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS. 2018 Dec 1;93:790–9.
34. Uenaldi O, Engin D, Cirak MY. Comparison of agar screening plates and double disk synergy method in detection of extended-spectrum beta-lactamase production. Mikrobiyol Bul. 2007 Jul;41(3):369–76.
 1. Bilman FB, Can F, Colakoglu S, Dolapci I, Demirbilek M, Kaya M, et al. THE PERFORMANCE OF TWO DIFFERENT CHROMOGENIC MEDIA FOR THE DIAGNOSIS OF EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING STRAINS. MIKROBIYOLOJİ BULTENİ. 2010 Jan;44(1):105–10.

Yönetimimde tamamlanmış yüksek lisans tezleri

1. Didem Molla. *Escherichia coli*'de HETEROLOG REKOMBİNANT PROTEİN EKSPRESYONU SIRASINDA OLUŞAN STRES YANITININ İNCELENMESİ. 2013, Ankara.
2. Aslınur Gülnaz Öztürk. “QUORUM SENSING”İN *Esherichia coli*'DE ANTİMİKROBİYAL DİRENCİNDEN SORUMLU MUTASYONLARIN OLUŞUMUNDAKİ ROLÜNÜN ARAŞTIRILMASI. 2014, Ankara.
3. Pelin Kolçak. Rekombinant insan interferon gamma peptidinin bakteriyel ve maya ekspresyon sistemleri kullanılarak üretimi. Kasım 2014 tarihinde tamamlanması öngörülüyor. TÜBİTAK öncelikli alan bursu ile destekleniyor
4. Ceren Can: Rekombinant insan insulün peptidinin bakteriyel ve maya ekspresyon sistemi kullanılarak üretimi. Kasım 2014 tarihinde tamamlanması öngörülüyor. TÜBİTAK öncelikli alan bursu ile destekleniyor
5. Pelin Kolçak. CHO Hücrelerinde Monoklonal Antikor Üretimi Sırasında XBP-1 Aşırı Ekspresyonunun ER Stres ve Glikozilasyon Arasındaki İlişkiye Etkisinin Tanımlanması (Devam ediyor)
6. Sema Karabudak. Rekombinant Immunoglobulin G1 Monoklonal Antikoruğunun *Kluyveromyces lactis* Maya Ekspresyon Sistemi Kullanılarak Üretimi (Devam ediyor)
7. Ege Soydemir. Özgün bir ışık kontrollü t7 promotörü-GFP ifade sisteminin geliştirilmesi ve GFP ifadesinin incelenmesi. Haziran 2019. Yüksek lisans tezi, tamamlandı
8. Gözde Ertüzün. Yeşil Floresan Protein İfadeleyen *Escherichia coli* Hücre Fabrikalarında Fenotipik Heterojenitenin Adaptasyona Etkisi. Ocak 2021 Yüksek lisans tezi, tamamlandı
9. Ayça Arslanhan. SARS-Cov-2'nin hızlı teşhisine yönelik apta-biyosensör geliştirilmesi. Doktora tezi, devam ediyor.
10. Merve Aksüt. Kimerik Pilin Rekombinant Aşı Üretim Platformu Geliştirilmesi. Yüksek

Lisans Tezi, devam ediyor.

Yurt içi patent

1. Engin ED, Türet S, Ünal S, Dumlu Ş, Yalınay Çırak M. Helicobacter pylori DNA'sının ve makrolid dirençli genotiplerin tava proplar kullanılarak polimeraz zincirleme tepkimesi ile saptanması. 2004 02876.

Verilen yüksek lisans ve doktora dersleri

1. Temel Biyoteknoloji Teknikleri Ve Uygulaması (400100711150)
2. Biyoteknoloji İçin Mikrobiyoloji II (400100801180)
3. Biyoteknoloji İçin Sentetik Biyoloji (400100801190)
4. İmmünoloji Ve İmmünolojik Teknikler (400100710111)
5. Biyonesneler İle Algoritma Ve Yazılım Geliştirme (400200710021)

Düzenlenen ulusal bilimsel toplantılar

1. ... Engin D... (toplam 18 kişi). Helicobacter pylori Sempozyumu. 9 – 11 Kasım 2005, Ankara.
2. Yamaç K, Açık L, Doğu G, Gürer İ, Şener B, Sultansoy S, Engin D. Bilim ve Teknoloji Stratejileri Çalıştayı, 31 Mayıs – 1 Haziran 2006, Ankara.
3. Akçelik M, Engin D, Ergül A, Aras S, Yıldırım B, Yener B, Altuner M. 9. Ankara Biyoteknoloji Günleri. 2011, Ankara.
4. ..., Engin D, ... XIth Ankara Biotechnology Days – Therapeutic Peptides and Antibodies: Design & Manufacturing Workshop. Ankara, 20 – 21 May 2015.